References on the Administration of Growth Factors
Using ALZET^® Osmotic Pumps

1. Epidermal Growth Factor

P8153 Bauer,S., Patterson,P.H. Leukemia inhibitory factor promotes neural stem cell self-renewal in the adult brain. Journal of Neuroscience 2006; 26(-46-):12089-12099. >>> Ara-C; leukemia inhibitory factor, recomb. mouse; epidermal growth factor, recomb. human; Saline; PBS; BSA; CSF/CNS; Mice; 1003D; 1007D; 1, 3, 6, 7, days; Controls received mp w/ vehicle; ALZET brain infusion kit 2 or 3 used; peptides; animal info (adult, male, C57BL/6J, 2-6 months old).

P8024 Ohta,Y., Nagai,M., Nagata,T., Murakarni,T., Nagano,I., Narai,H., Kurata,T., Shiote,M., Shoji,M., Abe,K. Intrathecal injection of epidermal growth factor and fibroblast growth factor 2 promotes proliferation of neural precursor cells in the spinal cords of mice with mutant human SOD1 gene. Journal of Neuroscience Research 2006; 84(-5-):980-992. >>> Epidermal growth factor; fibroblast growth factor; PBS; CSF/CNS (intrathecal, lumbar region); Mice; 2001; 7 days; Controls received mp w/ vehicle; animal info (100 days old); no body weight changes after implantation of pumps.

P7808 Karimi-Abdolrezaee,S., Eftekharpour,E., Wang,J., Morshead,C.M., Fehlings,M.G. Delayed transplantation of adult neural precursor cells promotes remyelination and functional neurological recovery after spinal cord injury. Journal of Neuroscience 2006; 26(-13-):3377-3389. >>> Fibroblast growth factor, basic; epidermal growth factor; platelet-derived growth factor-AA; CSF, artificial; gentamycin; BSA; CSF/CNS (intrathecal); Rat; 1007D; 7 days; Peptides; animal info (female, Wistar, 250g., spinal cord injury, neural precursor cells transplantation).

P7781 Grimaldi,P., Rossi,F. Lack of neurogenesis in the adult rat cerebellum after Purkinje cell degeneration and growth factor infusion. European Journal of Neuroscience 2006; 23(-10-):2657-2668. >>> Epidermal growth factor, recomb. human; fibroblast growth factor, basic; fibroblast growth factor 8b, recomb. mouse; Phosphate buffer; CSF/CNS; Rat; 2002; 1, 7, 14 days; Controls received mp w/ vehicle; peptides; animal info (Wistar albino, 200-250g, 2-3 months old).

P7677 Ivanov,A., Gerzanich,V., Ivanova,S., DenHaese,R., Tsymbalyuk,O., Simard,J.M. Adenylate cyclase 5 and Kca1.1 channel are required for EGFR up-regulation of PCNA in native contractile rat basilar artery smooth muscle. JOURNAL OF PHYSIOLOGY-LONDON 2006; 570(-1-):73-84. >>> Epidermal growth factor; AG-1478; angiotensin II; iberiotoxin; CSF, artificial; saline; CSF/CNS (intrathecal, cisterna magna); SC; Rat; 2001; 2004; 1,3 days; 4 weeks; Controls received mp w/ aCSF; cardiovascular; peptides; animal info (female, wistar, 275-325 g); angiotensin II disolved in saline and was subcutaneously delivered for 4 weeks using the 2004 model pump.

P7683 Cellini,C., Xu,J., Buchmiller-Crair,T. Effect of epidermal growth factor on small intestinal sodium/glucose cotransporter-1 expression in a rabbit model of intrauterine growth retardation. Journal of Pediatric Surgery 2005; 40(-12-):1892-1897. >>> Epidermal growth factor, recomb. human; BSA; Rabbit (pregnant); 2ML1; ; Controls received mp w/ vehicle; animal info (New Zealand White, 3.2-4.5 kg).

P7424 Takemura,N.U. Evidence for neurogenesis within the white matter beneath the temporal neocortex of the adult rat brain. Neuroscience 2005; 134(-1-):121-132. >>> Epidermal growth factor; fibroblast growth factor-2; CSF, artificial; albumin, rat serum; CSF/CNS; Rat; 1003D; 3 days; Animal info (male, wistar, 11-12 weeks old, 260-280 g); Plastics One Cannula used.

P7178 Cellini,C., Xu,J., Arriaga,A., Buchmiller-Crair,T.L., Buchmiller-Crair,T.L. Effect of epidermal growth factor infusion on fetal rabbit intrauterine growth retardation and small intestinal development. Journal of Pediatric Surgery 2004; 39(-6-):891-897. >>> Epidermal growth factor, recomb.human; BSA; Intra-amniotic; Rabbit (pregnant); 2ML1; 7 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; no stress (see pg. 893); teratology; peptides; multiple pumps per animal (4).

P6989 Enwere,E., Shingo,T., Gregg,C., Fujikawa,H., Ohta,S., Weiss,S. Aging results in reduced epidermal growth factor receptor signaling, diminished olfactory neurogenesis, and deficits in fine olfactory discrimination. Journal of Neuroscience 2004; 24(-38-):8354-8365. >>> Epidermal growth factor, human recomb.; AraC; Saline; albumin, mouse serum; CSF/CNS; Mice; 1003D; 3 days; Controls received mp w/ vehicle; peptides.

P6924 Avissar,N.E., Ziegler,T.R., Toia,L., Gu,L., Ray,E.C., Berlanga-Acosta,J., Sax,H.C. ATBO/ASCT2 expression in residual rabbit bowel is decreased after massive enterectomy and is restored by growth hormone treatment. Journal of Nutrition 2004; 134(-9-):2173-2177. >>> Epidermal growth factor; Albumin; SC; Rabbit; 2ML2; 2 weeks.

P6493 Rooman,I., Bouwens,L. Combined gastrin and epidermal growth factor treatment induces islet regeneration and restores normoglycaemia in C57Bl6/J mice treated with alloxan. Diabetologia 2004; 47(-2-):259-265. >>> Gastrin I, rat; epidermal growth factor, recomb. human; DMSO; saline, physiological; acetic acid; BSA; IP; Mice; 1007D; 1 week; Controls received no treatment; peptides; 8% DMSO.

P6377 Jin,K.L., Sun,Y.J., Xie,L., Childs,J., Mao,X.O., Greenberg,D.A. Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-4-):399-408. >>> Epidermal growth factor, heparin binding; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral).

P7431 Ray,E.C., Avissar,N.E., Vukcevic,D., Toia,L., Ryan,C.K., Berlanga-Acosta,J., Sax,H.C. Growth hormone and epidermal growth factor together enhance amino acid transport systems B0,+ and A in remnant small intestine after massive enterectomy. J.Surg.Res. 2003/8; 113(-2-):257-263. >>> Epidermal growth factor; Albumin; SC; Rabbit; 2 weeks; Controls received mp w/ vehicle; replacement therapy (enterectomy); no stress (see pg. 258-259).

P6712 Bashir,O., FitzGerald,A.J., Berlanga-Acosta,J., Playford,R.J., Goodlad,R.A. Effect of epidermal growth factor administration on intestinal cell proliferation, crypt fission and polyp formation in multiple intestinal neoplasia (Min) mice. Clinical Science 2003; 105(-3-):323-330. >>> Epidermal growth factor, recomb. human; SC; Mice; 2004; 4 weeks; Controls received mp w/ saline; cancer (intestinal adenoma; colon); peptides.

P6364 Gregg,C., Weiss,S. Generation of functional radial glial cells by embryonic and adult forebrain neural stem cells. Journal of Neuroscience 2003; 23(-37-):11587-11601. >>> Fibroblast growth factor-2; epidermal growth factor; transforming growth factor; Saline; serum albumin; CSF/CNS; Mice; 1007D; 6,12 days; Pumps replaced at day 7 for 12 d EGF infusions.

P6007 Ray,E.C., Avissar,N.E., Vukcevic,D., Toia,L., Ryan,C.K., Berlanga-Acosta,J., Sax,H.C. Growth hormone and epidermal growth factor together enhance amino acid transport systems B0,+ and a in remnant small intestine after massive enterectomy. Journal of Surgical Research 2003; 115(-1-):164-170. >>> Epidermal growth factor; Albumin; SC; Rabbit; 2 weeks; Controls received mp w/ vehicle; pump model not listed; EGF in 2% albumin.

P5952 Yang,J., Zhao,J.B., Zeng,Y.J., Gregersen,H. Biomechanical properties of ileum after systemic treatment with epithelial growth factor. WORLD JOURNAL OF GASTROENTEROLOGY 2003; 9(-10-):2278-2283. >>> Epidermal growth factor; SC; Rat; 2001; 2,4,7,14 days; Controls received mp w/ vehicle; pumps replaced once after 7 days for the 14 day study; peptides; EGF was human recomb..

P5915 Calza,L., Giuliani,A., Fernandez,M., Pirondi,S., D'Intino,G., Aloe,L., Giardino,L. Neural stem cells and cholinergic neurons: Regulation by immunolesion and treatment with mitogens, retinoic acid, and nerve growth factor. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O F AMERICA 2003; 100(-12-):7325-7330. >>> Epidermal growth factor; fibroblast growth factor, basic; Nerve growth factor; PBS, sterile; CSF/CNS; Rat; 2002; 28; Controls received mp w/ aCSF; pumps replaced every 14 days for 28 days; ALZET brain infusion kit used; peptides; behavioral study; NGF dissolved in PBS; EGF&FGF were infused for 14 days, followed by a 14 day infusion of NGF; stem cell related study.

P5681 Teramoto,T., Qu,J.H., Plumier,J.C., Moskowitz,M.A. EGF amplifies the replacement of parvalbumin-expressing striatal inter neurons after ischemia. Journal of Clinical Investigation 2003; 111(-8-):1125-1132. >>> Epidermal growth factor; PBS; BSA; CSF/CNS; Mice; 1007D; 7 days; peptides; ALZET brain infusion kit 2 used; 1mg/ml of albumin was added as carrier to solution to prevent degradation; ischemia (cerebral).

P5612 Yang,J., Zhao,J.B., Zeng,Y.J., Vinter-Jensen,L., Gregersen,H. Morphological properties of zero-stress state in rat large intestine during systemic EGF treatment. Digestive Diseases and Sciences 2003; 48(-3-):442-448. >>> Epidermal growth Factor; Saline; SC; Rat; 2001; 1 week; Controls received mp/w vehicle; peptides; EGF is human recombinant.

P5739 Zhao,J.B., Yang,J., Vinter-Jensen,L., Zhuang,F.Y., Gregersen,H. The morphometry and biomechanical properties of the rat small intestine after systemic treatment with epidermal growth factor. Biorheology 2002; 39(-6-):719-733. >>> Epidermal growth factor; SC; Rat; 2001; 14 days; Controls received mp w/ saline; peptides.

P5596 Doetsch,F., Petreanu,L., Caille,I., Garcia-Verdugo,J.M., Alvarez-Buylla,A. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron 2002; 36(-6-):1021-1034. >>> Epidermal growth factor; Ganciclovir; Saline; BSA; PBS; CSF/CNS; Mice; 1007D; 1002; 7 hours; 6 days; Controls received mp w/ vehicle; Gene therapy; peptides; EGF was diluted in BSA-containing saline and infused for 7 hours, or 6 days in 1007D pumps; Ganciclovir was diluted in PBS and infused for 6 days via 1002 pumps.

P5433 Nakatomi,H., Kuriu,T., Okabe,S., Yamamoto,S., Hatano,O., Kawahara,N., Tamura,A., Kirino,T., Nakafuku,M. Regeneration of hippocampal pyramidal neurons after ischemic brain injury by recruitment of endogenous neural progenitors. Cell 2002; 110(-4-):429-441. >>> Fibroblast growth factor 2; Epidermal growth factor; Ara-C; CSF, artificial; Albumin, rat serum; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; Ara-C is also called cytosine beta-D-arabinofuranoside (antimitotic drug); ischemia (cerebral).

P5392 Martens,D.J., Seaberg,R.M., van der Kooy,D. In vivo infusions of exogenous growth factors into the fourth ventricle of the adult mouse brain increase the proliferation of neural progenitors around the fourth ventricle and the central canal of the spinal cord. European Journal of Neuroscience 2002; 16(-6-):1045-1057. >>> Fibroblast growth factor 2; Epidermal growth factor; Heparin; Saline; Albumin, mouse; CSF/CNS (fourth ventricle); CSF/CNS; Mice; 6 days; Controls received mp w/ vehicle; peptides; EGF and FGF were infused alone or together, with or without heparin; heparin was added to prevent FGF degradation and to help present FGF to its receptor.

P5350 Bachoo,R.M., Maher,E.A., Ligon,K.L., Sharpless,N.E., Chan,S.S., You,M.J.J., Tang,Y., DeFrances,J., Stover,E., Weissleder,R., Rowitch,D.H., Louis,D.N., DePinho,R.A. Epidermal growth factor receptor and Ink4a/Arf: Convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. CANCER CELL 2002; 1(-3-):269-277. >>> Epidermal growth factor; Saline; albumin, mouse serum; CSF/CNS; Mice; 1007D; 7 days; Peptides.

P5220 Kojima,A., Tator,C.H. Intrathecal administration of epidermal growth factor and fibroblast growth factor 2 promotes ependymal proliferation and functional recovery after spinal cord injury in adult rats. J Neurotrauma 2002/2; 19(-2-):223-238. >>> Epidermal growth factor; Fibroblast growth factor 2; Albumin, rat serum; Gentamicin sulfate; CSF, artificial; CSF/CNS (intrathecal); Rat; 2002; 3 or 14 days; Controls received mp w/ vehicle; good methods (p. 224); lynch coil used; pump filled w/ saline; mineral oil spacer used to separate saline in pump from agent solution in catheter; agents infused separatedly or concomittantly in the same pump;.

top of page

2. Fibroblast Growth Factor

R0239 Richardson,R.T., Noushi,F., O'Leary,S. Inner ear therapy for neural preservation. AUDIOLOGY AND NEURO-OTOLOGY 2006; 11(-6-):343-356. >>> Nerve groth factor; NT-3; adenovirus; brain-derived neurotrophic factor; perilymph, artificial; glial-derived neurotrophic factor; ciliary neurotrophic factor; fibroblast growth factor, acidic; fibroblast growth factor-1; fibroblast growth factor-2; fibroblast growth factor, basic; Ear (cochlea); ear (scala tympani); Guinea-pig; 1,2,4,8 weeks; 15-60, 11-12, 26 days; Comparison of polymers, hydrogels, gene therapy, cell-based therapy, and injections vs. mp; long-term study; pumps replaced; no stress (see pg. 350); half-life (p. 344), short in blood; gene therapy; peptides; animal info (deafened); Table 2; "The mini-osmotic pump device is ideally suited to studying the effects of neurotrophic factors in the cochlea experimentally." (p. 350).

P8294 Yagi,H., Ueda,M., Jinno,H., Aiura,K., Mikami,S., Tada,H., Seno,M., Yamada,H., Kitajima,M. Anti-tumor effect in an in vivo model by human-derived pancreatic RNase with basic fibroblast growth factor insertional fusion protein through antiangiogenic properties. CANCER SCIENCE 2006; 97(-12-):1315-1320. >>> Fibroblast growth factor, basic; CL-RFN89; PBS; Mice (nude); ; Cancer (carcinoma); animal info (4 weeks old, female, Balb/C, nude); antiangiogenesis; tumor cells in right flank, agent is an insertional-fusion protein.

P8291 Won,S.J., Xie,L., Kim,S.H., Tang,H.D., Wang,Y.M., Mao,X.O., Banwait,S., Jin,K.L. Influence of age on the response to fibroblast growth factor-2 treatment in a rat model of stroke. Brain Research 2006; 1123(--):237-244. >>> Fibroblast growth factor-2; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; animal info (24 month old/3 month old, male, Fisher); ischemia (cerebral).

P8096 Gosain,A., Matthies,A.M., Dovi,J.V., Barbul,A., Gamelli,R.L., DiPietro,L.A. Exogenous pro-angiogenic stimuli cannot prevent physiologic vessel regression. Journal of Surgical Research 2006; 135(-2-):218-225. >>> Vascular endothelial growth factor 164, recomb.; platelet-dreived growth factor; fibroblast growth factor-2; Wound site; Mice; 2002; 11 days; Controls received mp w/ PBS; functionality of mp verified by VEGF levels in wound sponges, residual volume; stability verified by activity of residual VEGF in endothelial cell cord formation assay (fig.4); cardiovascular; peptides; animal info (female, BALB/c, 8-9 wks old, implanted sponge wounds); "The activity of VEGF isolated from the pump was comparable to fresh recombinant VEGF 164, confriming that the recombinant growth factors present in the mini-osmotic pump retain robust biological activity." (p.221).

P8042 Wente,W., Efanov,A.M., Brenner,M., Kharitonenkov,A., Koester,A., Sandusky,G.E., Sewing,S., Treinies,I., Zitzer,H., Gromada,J. Fibroblast growth factor-21 improves pancreatic beta-cell function and survival by activation of extracellular signal-regulated kinase 1/2 and Akt signaling pathways. Diabetes 2006; 55(-9-):2470-2478. >>> Fibroblast growth factor-21; Saline; SC; Mice; 1002; 8 weeks; FGF-21 plasma levels taken; long-term study; pumps replaced every two weeks; animal info (C57BL/6, 8 weeks old); diabetes.

P7799 Reimers,D., Herranz,A.S., az-Gil,J.J., Lobo,M.V.T., Paino,C.L., Alonso,R., Asensio,M.J., Gonzalo-Gobernado,R., Bazan,E. Intrastriatal infusion of liver growth factor stimulates dopamine terminal sprouting and partially restores motor function in 6-hydroxydopamine-lesioned rats. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2006; 54(-4-):457-465. >>> Liver growth factor, rat; fibroblast growth factor, rat basic; Saline, physiological; albumin, rat; CSF/CNS (striatum); CSF/CNS; Rat; 2002; ; Controls received mp w/ vehicle, or no treatment; ALZET brain infusion kit used; peptides; neurodegenerative (Parkinson's disease); animal info (female, Sprague-Dawley, 220-250g., 6-OHDA induced lesions).

P7929 Tuereyen,K., Vemuganti,R., Bowen,K.K., Sailor,K.A., Dempsey,R.J. EGF and FGF-2 infusion increases post-ischemic neural progenitor cell proliferation in the adult rat brain. Neurosurgery 2005; 57(-6-):1254-1262. >>> Endothelial growth factor; fibroblast growth factor-2; CSF, artificial; BSA; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; peptides; ischemia (cerebral); animal info (adult, male, SHR, 250-275 grams); MCAO; 0.1% BSA added.

P7568 Pieper,A.A., Wu,X.L., Han,T.W., Estill,S.J., Dang,Q.Y., Wu,L.C., Reece-Fincanon,S., Dudley,C.A., Richardson,J.A., Brat,D.J., McKnight,S.L. The neuronal PAS domain protein 3 transcription factor controls FGF-mediated adult hippocampal neurogenesis in mice. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2005; 102(-39-):14052-14057. >>> Fibroblast growth factor, basic; CSF, artificial; CSF/CNS; Mice; 1007D; 4 days; Controls received mp w/ vehicle; animal info (male, 3 month old); also known as FGF2.

P7328 Kharitonenkov,A., Shiyanova,T.L., Koester,A., Ford,A.M., Micanovic,R., Galbreath,E.J., Sandusky,G.E., Hammond,L.J., Moyers,J.S., Owens,R.A., Gromada,J., Brozinick,J.T., Hawkins,E.D., Wroblewski,V.J., Li,D.S., Mehrbod,F., Jaskunas,S.R., Shanafelt,A.B. FGF-21 as a novel metabolic regulator. Journal of Clinical Investigation 2005; 115(-6-):1627-1635. >>> Fibroblast growth Factor-21; Saline; SC; Mice; 8 weeks; Controls received mp w/ vehicle; replacement therapy (diabetic, db/db); comparison of SC injections vs. mp (minipump used to study mitogenicity during longer exposure); long-term study.

P6944 Motoyoshi,K., Hyodo,M., Yamagata,T., Gyo,K. Restoring vocal fold movement after transection and immediate suturing of the recurrent laryngeal nerve with local application of basic fibroblast growth factor: An experimental study in the rat. Laryngoscope 2004; 114(-7-):1247-1252. >>> Fibroblast growth factor, basic; PBS; BSA; CSF/CNS (recurrent laryngeal nerve); Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; good methods (p. 1248); nerve infusion schematic (p. 1248).

P6920 Aronson,J. The Nicolas Andry Award - Modulation of distraction osteogenesis in the aged rat by fibroblast growth factor. Clinical Orthopaedics and Related Research 2004; (-425-):264-283. >>> Fibroblast growth factor, recomb. human; dihydrotestosterone; Sodium citrate; SC; bone (tibia); Rat; 1007D; 1002; 2002; 7, 14 days; Functionality of mp verified by residual volume; comparison of injections vs. mp; post op. care (heated cage/analgesics); pumps used for systemic or targeted delivery; silastic tubing used; "The pumps were well tolerated without inflammatory reaction, infection, or pain." (p. 273); picture of pump and catheter (radiograph image) p. 277, fig 10A-B; animal info (Sprague-Dawley).

P6621 Prior,B.M., Lloyd,P.G., Ren,J., Li,Z., Yang,H.T., Laughlin,M.H., Terjung,R.L. Arteriogenesis: Role of nitric oxide. ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH 2003; 10(-4-5-):207-216. >>> Fibroblast growth factor; heparinase I; IA (iliac); 2 weeks; Dose-response (p. 213); the heparinase I infusion group targeted the contralateral iliac vessel; pump or animal model not mentioned.

P6123 Cao,R.H., Brakenhielm,E., Pawliuk,R., Wariaro,D., Post,M.J., Wahlberg,E., Leboulch,P., Cao,Y.H. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nature Medicine 2003; 9(-5-):604-613. >>> Fibroblast growth factor; platelet-derived growth factor; IA (femoral); Rabbit; 7 days; ischemia (hind-limb).

P6072 Goodman,S.B., Song,Y., Yoo,J.Y., Fox,N., Trindade,M.C.D., Kajiyama,G., Ma,T., Regula,D., Brown,J., Smith,R.L. Local infusion of FGF-2 enhances bone ingrowth in rabbit chambers in t he presence of polyethylene particles. JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A 2003; 65A(-4-):454-461. >>> Fibroblast growth factor 2; Heparin; BSA; PBS; Bone (tibia); Rabbit; 2004; 3 weeks; Dose-response (p. 459); pumps replaced every 3 weeks to begin new studies; bone chamber; pump/chamber schematics (p. 455); 16.6 ug/ml of heparin.

P6009 Srivastava,S., Terjung,R.L., Yang,H.T. Basic fibroblast growth factor increases collateral blood flow in spontaneously hypertensive rats. American Journal of Physiology-Heart and Circulatory Physiology 2003; 285(-3-):H1190-H1197. >>> Fibroblast growth factor, basic; Sodium citrate; glycerol; PBS; IA (iliac); Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume p. H1192; antihypertensive; post op. care (topical antibiotic powder); "The pump was housed in a tunnel under the skin in the left groin area; this placement did not hamper hindlimb movement while rats were walking on the treadmill." p. H1191; behavioral study; "There were no signs of ischemia or necrosis and no presence of infection or complications from the osmotic pumps..." p. H1192.

P5682 Heeschen,C., Weis,M., Cooke,J.P. Nicotine promotes arteriogenesis. Journal of the American College of Cardiology 2003; 41(-3-):489-496. >>> Nicotine; fibroblast growth factor, basic; PBS; IA (iliac); Rabbit; 2ML2; 18 days; Controls received mp w/ vehicle..

P5618 Tanaka,H., Wakisaka,A., Ogasa,H., Kawai,S., Liang,C.T. Effects of basic fibroblast growth factor on osteoblast-related gene expression in the process of medullary bone formation induced in rat femur. JOURNAL OF BONE AND MINERAL METABOLISM 2003; 21(-2-):74-79. >>> Fibroblast growth factor, basic; Bone (femoral); Rat; 6 days; Controls received mp/w vehicle.

P5805 Scheinowitz,M., Kotlyar,A.A., Zimand,S., Leibovitz,I., Varda-Bloom,N., Ohad,D., Goldberg,I., Engelberg,S., Savion,N., Eldar,M. Effect of basic fibroblast growth factor on left ventricular geometry in rats subjected to coronary occlusion and reperfusion. ISRAEL MEDICAL ASSOCIATION JOURNAL 2002; 4(-2-):109-113. >>> Fibroblast growth factor 2; Epidermal growth factor; Ara-C; CSF, artificial; Albumin, rat serum; CSF/CNS; Rat; 1003D; 1 week; Controls received mp w/ vehicle; Ara-C is also called cytosine beta-D-arabinofuranoside (antimitotic drug); ischemia (cerebral).

P5340 Scholz,D., Ziegelhoeffer,T., Helisch,A., Wagner,S., Friedrich,C., Podzuweit,T., Schaper,W. Contribution of arteriogenesis and angiogenesis to postocclusive Hindlimb perfusion in mice. Journal of Molecular and Cellular Cardiology 2002; 34(-7-):775-787. >>> Fibroblast growth factor 2; PBS; IA (femoral); Mice; 1007D; ; Controls received mp w/ vehicle; peptides.

P5281 Hermans,J.J., van Essen,H., Struijker-Boudier,H.A., Johnson,R.M., Theeuwes,F., Smits,J.F. Pharmacokinetic advantage of intrapericardially applied substances in the rat. J Pharmacol Exp.Ther 2002/5; 301(-2-):672-678. >>> Heparin; Fibroblast growth factor 2; Immunoglobulin G, rat; PBS; Albumin, rat serum; fluorescein; texas red; IV (jugular); intrapericardial; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality verified by measuring drug concentration in residual volume; plasma and pericardial fluid drug levels checked; comparison of bolus injection vs. mp; cardiovascular; DURECT-authored; rhFGF and rat serum albumin labeled w/ Texas red; rat IgG was labeled w/ fluorescein Isothiocyanate (FITC).

P5271 Davies,M.M., Mathur,P., Carnochan,P., Saini,S., Allen-Mersh,T.G. Effect of manipulation of primary tumour vascularity on metastasis in an adenocarcinoma model. Br.J Cancer 2002/1/7; 86(-1-):123-129. >>> Fibroblast growth factor, basic; Saline; IV (jugular); Intratumoral; Rat; 2004; 28 days; Controls received mp w/ vehicle; tissue perfusion (intratumoral); cancer; peptides; bFGF delivered either by systemic IV infusion or intratumorally.

P5059 Davies,M.M., Burke,D., Carnochan,P., Glover,C., Kaur,S., Allen-Mersh,T.G. Basic fibroblast growth factor infusion increases tumour vascularity, blood flow and chemotherapy uptake. Acta Oncologica 2002; 41(-1-):84-90. >>> Fibroblast Growth Factor, Basic; Saline; IV (jugular); Intratumoral;; rat; 10, 14, or 28 days; controls received mp w/ vehicle; tissue perfusion (tumor); cancer; one group received 10-day saline infusion by pump, followed by 14-day bFGF or saline infusion from a second pump.

top of page

3. Hepatocyte Growth Factor

P8085 Date,I., Takagi,N., Takagi,K., Tanonaka,K., Funakoshi,H., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor attenuates cerebral ischemia-induced increase in permeability of the blood-brain barrier and decreases in expression of tight junctional proteins in cerebral vessels. Neuroscience Letters 2006; 407(-2-):141-145. >>> Hepatocyte growth factor, recomb. human; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ physiological saline; peptides; ischemia (cerebral); animal info (male, Wistar, 180-220g, microsphere-induced cerebral embolism).

P8009 Niimura,M., Takagi,N., Takagi,K., Mizutani,R., Ishihara,N., Matsumoto,K., Funakoshi,H., Nakamura,T., Takeo,S. Prevention of apoptosis-inducing factor translocation is a possible mechanism for protective effects of hepatocyte growth factor against neuronal cell death in the hippocampus after transient forebrain ischemia. Journal of Cerebral Blood Flow and Metabolism 2006; 26(-11-):1354-1365. >>> Hepatocyte growth factor; Saline; CSF/CNS (right hippocampal region); Rat; 1003D; 3 days; Animal info (male, Wistar, 200-250 grams); ischemia (cerebral); tissue perfusion (hippocampal region).

P8008 Niimura,M., Takagi,N., Takagi,K., Mizutani,R., Tanonaka,K., Funakoshi,H., Matsumoto,K., Nakamura,T., Takeo,S. The protective effect of hepatocyte growth factor against cell death in the hippocampus after transient forebrain ischemia is related to the improvement of apurinic/apyrimidinic endonuclease/redox factor-1 level and inhibition of NADPH oxidase activity. Neuroscience Letters 2006; 407(-2-):136-140. >>> Hepatocyte growth factor; CSF/CNS (right hippocampal region); Rat; 1003D; 3 days; Animal info (male, Wistar, 200-250 grams); ischemia (cerebral); tissue perfusion (hippocampal region).

P7925 Tada,T., Zhan,H., Tanaka,Y., Hongo,K., Matsumoto,K., Nakamura,T. Intraventricular administration of hepatocyte growth factor treats mouse communicating hydrocephalus induced by transforming growth factor beta 1. NEUROBIOLOGY OF DISEASE 2006; 21(-3-):576-586. >>> Hepatocyte growth factor, recomb. human; PBS; BSA; CSF/CNS; Mice; 1007D; 1002; 7,14 days; Animal info (C57BL/6, 10-days old).

P7846 Niimura,M., Takagi,N., Takagi,K., Funakoshi,H., Nakamura,T., Takeo,S. Effects of hepatocyte growth factor on phosphorylation of extracellular signal-regulated kinase and hippocampal cell death in rats with transient forebrain ischemia. European Journal of Pharmacology 2006; 535(-1-3-):114-124. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS (hippocampus); Rat; 1003D; 1, 2, 3 days; 0.5, 1, 6 hours; Controls received mp w/ vehicle; dose-response (fig. 2); peptides; ischemia (cerebral); animal info (male, Wistar, 200-250g., transient forebrain ischemia by carotid artery occlusion); mp primed in 37 celsius saline.

P7654 Timmapuri,S.J., Otterburn,D.M., Arafat,H., Schwartz,M.Z. Hepatocyte growth factor increases glucagon immunoreactivity in jejunal cells during intestinal adaptation. Journal of Pediatric Surgery 2006; 41(-1-):150-153. >>> Hepatocyte growth factor; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ saline; animal info (male, Sprague-Dawley, adult, 200-225 g); PE catheter used.

P7668 Hasuike,S., Ido,A., Uto,H., Moriuchi,A., Tahara,Y., Numata,M., Nagata,K., Hori,T., Hayashi,K., Tsubouchi,H. Hepatocyte growth factor accelerates the proliferation of hepatic oval cells and possibly promotes the differentiation in a 2-acetylaminofluorene/partial hepatectomy model in rats. Journal of Gastroenterology and Hepatology 2005; 20(-11-):1753-1761. >>> Hepatocyte growth factor, recomb. human; PBS; IP; Rat; 7 days; Controls received mp w/ vehicle; functionality of mp verified by human HGF serum levels; replacement therapy (hepatectomy); half-life (pg. 1758)<3 min; animal info (male, Fisher, 8 wk. old).

P7262 Ohda,Y., Hori,K., Tomita,T., Hida,N., Kosaka,T., Fukuda,Y., Miwa,H., Matsumoto,T. Effects of hepatocyte growth factor on rat inflammatory bowel disease models. Digestive Diseases and Sciences 2005; 50(-5-):914-921. >>> Hepatocyte growth factor, recomb. human; IP; Rat; 2001; 7 weeks; Controls received mp w/ PBS; functionality of mp verified by serum rhHGF levels.

P7047 Biswas,P., Roy,A., Gong,R.J., Yango,A., Tolbert,E., Centracchio,J., Dworkin,L.D. Hepatocyte growth factor induces an endothelin-mediated decline in glomerular filtration rate. American Journal of Physiology-Renal Physiology 2005; 288(-1-):F8-F15. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 1 week; Controls received mp w/ vehicle; functionality of mp verified by plasma and urine HGF levels; comparison of acute IV infusions vs. mp; no stress (see pg. F12); post op. care (atipamezole).

P6951 Isogawa,K., Akiyoshi,J., Kodama,K., Matsushita,H., Tsutsumi,T., Funakoshi,H., Nakamura,T. Anxiolytic effect of hepatocyte growth factor infused into rat brain. NEUROPSYCHOBIOLOGY 2005; 51(-1-):34-38. >>> Hepatocyte growth factor; Ringer's solution; CSF/CNS; Rat; 1003D; 3 days; ALZET brain infusion kit used; behavioral study.

P6816 Date,I., Takagi,N., Takagi,K., Kago,T., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor improved learning and memory dysfunction of microsphere-embolized rats. Journal of Neuroscience Research 2004; 78(-3-):442-453. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS; Rat; 2001; 7 days; Controls received sham ischemia operation and were HGF-untreated; dose-response (fig. 1); ischemia (cerebral); memory.

P6779 Date,I., Takagi,N., Takagi,K., Kago,T., Matsumoto,K., Nakamura,T., Takeo,S. Hepatocyte growth factor attenuates cerebral ischemia-induced learning dysfunction. Biochemical and Biophysical Research Communications 2004; 319(-4-):1152-1158. >>> Hepatocyte growth factor, recomb. human; Saline, physiological; CSF/CNS; Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig 1); cardiovascular; ischemia (cerebral); learning/memory study.

P6413 Arthur,L.G., Schwartz,M.Z., Kuenzler,K.A., Birbe,R. Hepatocyte growth factor treatment ameliorates diarrhea and bowel inflammation in a rat model of inflammatory bowel disease. Journal of Pediatric Surgery 2004; 39(-2-):139-143. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 2002; 14 days; Controls received mp w/ vehicle.

P6391 Dworkin,L.D., Gong,R.J., Tolbert,E., Centracchio,J., Yano,N., Zanabli,A.R., Esparza,A., Rifai,A. Hepatocyte growth factor ameliorates progression of interstitial fibrosis in rats with established renal injury. Kidney International 2004; 65(-2-):409-419. >>> Hepatocyte growth factor; Saline; IV (jugular); Rat; 2002; 2 weeks; Controls received mp w/ vehicle; PE-50 used.

P6700 Mori,T., Shimizu,A., Masuda,Y., Fukuda,Y., Yamanaka,N. Hepatocyte growth factor-stimulating endothelial cell growth and accelerating glomerular capillary repair in experimental progressive glomerulonephritis. NEPHRON EXPERIMENTAL NEPHROLOGY 2003; 94(-2-):E44-E54. >>> Hepatocyte growth factor, recomb. human; Saline; IP; Rat; 2ML1; 7 days; Controls received mp w/ vehicle; nephrology.

P6414 Arthur,L.G., Kuenzler,K.A., Schwartz,M.Z. Hepatocyte growth factor ameliorates inflammatory bowel disease in a rat model. JOURNAL OF GASTROINTESTINAL SURGERY 2003; 7(-8-):1062-1067. >>> Hepatocyte growth factor; Tris buffer; IV (jugular); Rat; 2002; 14 days; Peptides; one group of rats received HGF intravenously (jugular) and another received HGF intravenously via the terminal ileal.

P5940 Davies,G., Mason,M.D., Martin,T.A., Parr,C., Watkins,G., Lane,J., Matsumoto,K., Nakamura,T., Jiang,W.G. The HGF/SF antagonist NK4 reverses fibroblast- and HGF-induced prostat e tumor growth and angiogenesis in vivo. International Journal of Cancer 2003; 106(-3-):348-354. >>> Hepatocyte growth factor; NK4; BSA; SC; Mice (nude); 2004; 28 days; Controls received mp w/ vehicle; cancer (prostate); NK4 (HGF/SF antagonist) is recomb. human.

P5892 Jin,H.K., Yang,R.H., Li,W., Ogasawara,A.K., Schwall,R., Eberhard,D.A., Zheng,Z., Kahn,D., Paoni,N.F. Early treatment with hepatocyte growth factor improves cardiac function in experimental heart failure induced by myocardial infarction. Journal of Pharmacology and Experimental Therapeutics 2003; 304(-2-):654-660. >>> Hepatocyte growth factor; Saline; heparin; IV (jugular); Rat; 2001; 6 days; Controls received mp w/ vehicle; functionality of mp verified by blood pressure taken&plasma levels taken; cardiovascular; peptides; recomb human HGF used; 50 U/ml of heparin.

P6235 Kuenzler,K.A., Arthur,L.G., Schwartz,M.Z. A possible mechanism for prevention of intestinal programmed cell death after ischemia-reperfusion injury by hepatocyte growth factor pretreatment. Journal of Pediatric Surgery 2002; 37(-12-):1696-1699. >>> Hepatocyte growth factor, recomb. human; Tris buffer; IV (jugular); Rat; 1003D; 48-54 hours; Controls received mp w/ vehicle; peptides; ischemia (cardiac).

top of page

4. Insulin-like Growth Factor

P8385 Sferruzzi-Perri,A.N., Owens,J.A., Standen,P., Taylor,R.L., Heinemann,G.K., Robinson,J.S., Roberts,C.T. Early treatment of the pregnant guinea pig with IGFs promotes placental transport and nutrient partitioning near term. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 2007; 292(-3-):E668-E676. >>> Insulin-like growth factor I; Insulin-like growth factor II, recomb. human; Acetic acid; SC; Guinea-Pig (pregnant); 2002; 18 days; Controls received mp w/ vehicle; functionality of mp verified by IGF-I/II maternal circulation levels; peptides; animal info (female, IMVS colored, pregnant, 500g., 3-4 months old, gestation days 20-38).

P8370 Lopez-Lopez,C., Dietrich,M.O., Metzger,F., Loetscher,H., Torres-Aleman,I. Disturbed cross talk between insulin-like growth factor I and AMP-activated protein kinase as a possible cause of vascular dysfunction in the amyloid precursor protein/presenilin 2 mouse model of Alzheimer's disease. Journal of Neuroscience 2007; 27(-4-):824-831. >>> Insulin-like growth factor I, recomb. human; SC; Mice; 1002; Controls received mp w/ saline; functionality of mp verified by serum IGF-I levels; peptides; animal info (C57BL/6J, APP/PS2, 6 month old); neurodegenerative (Alzheimer's disease).

P8049 Kleinberg,D.L., Ruan,W.F., Yee,D., Kovacs,K.T., Vidal,S. Insulin-like growth factor (IGF)-I controls prostate fibromuscular development: IGF-I inhibition prevents both fibromuscular and glandular development in eugonadal mice. Endocrinology 2007; 148(-3-):1080-1088. >>> Insulin-like growth factor-1; growth hormone, bovine; insulin-like growth factor-1, binding protein; SC; Mice; 1007D; 7 days; Controls received mp w/ saline; peptides; animal info (ORX, 10 weeks old, male); drugs delivered alone or in combination.

P8387 Serose,A., Salmon,A., Fiszman,M.Y., Fromes,Y. Short-term treatment using insulin-like growth factor-1 (IGF-1) improves life expectancy of the delta-sarcoglycan deficient hamster. JOURNAL OF GENE MEDICINE 2006; 8(-8-):1048-1055. >>> Insulin-like growth factor I, recomb. human; SC; Hamster; 2002; 19 days; Controls received mp w/ Saline; cardiovascular; peptides; animal info (male, Syrian wt or CHF147, 7-8 months old, 100-150g.).

P8339 Schertzer,J.D., Lynch,G.S. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Therapy 2006; 13(-23-):1657-1664. >>> Insulin-like growth factor I; SC; Mice; 1002; 3, 10, 14 days; Controls received non-coding plasmid; functionality of mp verified by residual volume; comparison of gene transfer vs. mp; peptides; animal info (male, C57BL10, 12-14 weeks old, myotoxic tibialis anterior muscle injury).

P8170 Kobayashi,A., Iikubo,M., Kojima,I., Ikeda,H., Sakamoto,M., Sasano,T. Morphological and histopathological changes in tongues of experimentally developed acromegaly-like rats. Hormone and Metabolic Research 2006; 38(-3-):146-151. >>> Insulin-like growth factor-1, recomb. human; Saline; SC; Rat; 2002; 4 weeks; Controls received mp w/ vehicle; peptides; animal info (male, Wistar, 10 weeks old, 225 grams).

P7866 Lupien,S.B., Bluhm,E.J., Ishii,D.N. Effect of IGF-I on DNA, RNA, and protein loss associated with brain atrophy and impaired learning in diabetic rats. NEUROBIOLOGY OF DISEASE 2006; 21(-3-):487-495. >>> Insulin-like growth factor-I; Acetic acid; SC; Rat; 7-8 weeks; Controls received mp w/ vehicle; long-term study; pumps replaced every 18 days; peptides; neurodegenerative (Alzheimer's disease); animal info (male, Harlan Wistar, 10 wk. old).

P7855 Koopmans,G.C., Brans,M., Gomez-Pinilla,F., Duis,S., Gispen,W.H., Torres-Aleman,I., Joosten,E.A.J., Hamers,F.P.T. Circulating insulin-like growth factor I and functional recovery from spinal cord injury under enriched housing conditions. European Journal of Neuroscience 2006; 23(-4-):1035-1046. >>> Insulin-like growth factor-1, recomb. human; insulin-like growth factor-1, anti-; Saline; SC; Rat; 2004; 4 weeks; Controls received mp w/ vehicle; no stress (see pg. 1039); peptides; animal info (female, Wistar, 11 wk. old).

P7829 Toth,C., Brussee,V., Zochodne,D.W. Remote neurotrophic support of epidermal nerve fibres in experimental diabetes. Diabetologia 2006; 49(-5-):1081-1088. >>> Insulin; insulin-like growth factor-1; Saline; SC; CSF/CNS (intrathecal, lumbar); Rat; 2002; 1 month; Controls received mp w/ vehicle; replacement therapy (stz-induced diabetes); pumps replaced after 2 weeks; peptides; animal info (male, Sprague-Dawley, 300-350g.); comparison of SC mp vs. IT mp.

P7584 Darnaudery,M., Perez-Martin,M., Belizaire,G., Maccari,S., Garcia-Segura,L.M. Insulin-like growth factor 1 reduces age-related disorders induced by prenatal stress in female rats. NEUROBIOLOGY OF AGING 2006; 27(-1-):119-127. >>> Insulin-like growth factor I, recomb. human; Saline; CSF/CNS; Rat; 2004; 21 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; animal info (female, Sprague-Dawley 24 month old, 2 month old).

P7467 Oldroyd,S.D., Miyamoto,Y., Moir,A., Johnson,T.S., El Nahas,A.M., Haylor,J.L. An IGF-I antagonist does not inhibit renal fibrosis in the rat following subtotal nephrectomy. American Journal of Physiology-Renal Physiology 2006; 290(-3-):F695-F702. >>> Insulin-like growth factor I, receptor antagonist; SC; Rat; 2002; 2004; 10, 90 days; Controls received mp w/ vehicle, or sham operation; dose-response (fig. 3); long-term study; pumps replaced every 4 weeks; stability verified by storage in mp for 4 weeks; peptides; animal info (male, wistar, chronic kidney disease, 200-300 g); IGF-I receptor antagonist (JB3); mp primed 4 hr in 37C isotonic saline.

P7939 Shi,L., Linville,M.C., Tucker,E.W., Sonntag,W.E., Brunso-Bechtold,J.K. Differential effects of aging and insulin-like growth factor-1 on synapses in CA1 of rat hippocampus. Cerebral Cortex 2005; 15(-5-):571-577. >>> Insulin-like growth factor-1, recomb. human; Saline; CSF/CNS; Rat; 2002; 28 days; Controls received mp w/ vehicle; pumps replaced after 14 days; no stress (see pg. 573); ALZET brain infusion kit used; petides; animal info (male, fischer, Brown Norway F1, 29 months old); memory; aging.

P7621 Narai,H., Nagano,I., Ilieva,H., Shiote,M., Nagata,T., Hayashi,T., Shoji,M., Abe,K. Prevention of spinal motor neuron death by insulin-like growth factor-1 associating with the signal transduction systems in SOD(G93A) transgenic mice. Journal of Neuroscience Research 2005; 82(-4-):452-457. >>> Insulin-like growth factor I, recomb. human; CSF, artificial; CSF/CNS (intrathecal, subarachnoid space, lumbar); Mice (transgenic); 2004; 5-10 weeks; Controls received mp w/ vehicle; dose-response (fig 1); long-term study; pumps replaced every 4 weeks; neurodegenerative (Amyotrophic Lateral Sclerosis); animal info (C57BL/6J, female).

P7607 Fernandez,A.M., Carro,E.M., Lopez-Lopez,C., Torres-Aleman,I. Insulin-like growth factor I treatment for cerebellar ataxia: Addressing a common pathway in the pathological cascade?. BRAIN RESEARCH REVIEWS 2005; 50(-1-):134-141. >>> Insulin-like growth factor I; SC; CSF/CNS; Rat; mice; 1 month; 2 weeks; Peptides; neurodegenerative (cerebellar ataxia); Review, pg. 138, ref #21; "This long-term delivery system increases therapeutically available IGF-1 at least 30-fold as compared to single subcutaneous injections" (p. 138).

P7405 Fruchtman,S., Simmons,J.G., Michaylira,C.Z., Miller,M.E., Greenhalgh,C.J., Ney,D.M., Lund,P.K. Suppressor of cytokine signaling-2 modulates the fibrogenic actions of GH and IGF-I in intestinal mesenchymal cells. American Journal of Physiology-Gastrointestinal and Liver Physiology 2005; 289(-2-):G342-G350. >>> Insulin-like growth factor I-; growth hormone; Saline; SC; Mice (knockout); 5 days; Controls received mp w/ vehicle; peptides.

P7350 Slagter,B.J., Kittilson,J., Sheridan,M.A. Expression of somatostatin receptor mRNAs is regulated in vivo by growth hormone, insulin, and insulin-like growth factor-I in rainbow trout (Oncorhynchus mykiss). REGULATORY PEPTIDES 2005; 128(-1-):27-32. >>> Growth hormone, recomb. bovine; insulin, recomb. bovine; insulin-like growth factor. recomb. human; NaCl; IP; Fish (rainbow trout); 1007D; 21 days; Controls received mp w/ vehicle; peptides; post op. care (topical antibiotic ointment); at 14 degrees celsius, the 1007D infuses at 0.14 ul/hr for approximately 21 days.

P7346 Serose,A., Prudhon,B., Salmon,A., Doyennette,M.A., Fiszman,M.Y., Fromes,Y. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Research In Cardiology 2005; 100(-2-):161-170. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Hamster; 2004; ; Controls received mp w/ vehicle; peptides.

P7336 Zhu,Z.J., Jiang,W.Q., McGinley,J., Wolfe,P., Thompson,H.J. Effects of dietary energy repletion and IGF-1 infusion on the inhibition of mammary carcinogenesis by dietary energy restriction. MOLECULAR CARCINOGENESIS 2005; 42(-3-):170-176. >>> Insulin-like growth factor I; HCL; SC; Rat; 2001; 8 days; Peptides.

P7181 Hewitt,S.C., Collins,J., Grissom,S., Deroo,B., Korach,K.S. Global uterine Genomics in vivo: Microarray evaluation of the estrogen receptor alpha-growth factor cross-talk mechanism. MOLECULAR ENDOCRINOLOGY 2005; 19(-3-):657-668. >>> Epidemal growth factor; insulin-like growth factor I, LR3-; Acetic acid; IP; Mice; 24 hours; Controls received mp w/ vehicle; comparison of IP injections vs. mp.

P7166 Cool,J.C., Dyer,J.L., Xian,C.J., Butler,R.N., Geier,M.S., Howarth,G.S. Pre-treatment with insulin-like growth factor-I partially ameliorates 5-fluorouracil-induced intestinal mucositis in rats. GROWTH HORMONE&IGF RESEARCH 2005; 15(-1-):72-82. >>> Insulin-like growth factor I, recomb.human; Acetic acid; SC; Rat; 2002; 7 days; Controls received mp w/ vehicle, no stress (see pg. 75), cancer, peptides, orally administered IGF-1 degrades rapidly in the gastric environment.

P7142 Ruan,W.F., Monaco,M.E., Kleinberg,D.L. Progesterone stimulates mammary gland ductal morphogenesis by synergizing with and enhancing insulin-like growth factor-I action. Endocrinology 2005; 146(-3-):1170-1178. >>> Insulin-like growth factor I, des(1-3); SC; Mice; 1007D; 1002; 5, 28 days; Controls received placebo; replacement therapy (IGF-I [-/-], oophorectomy); pumps replaced at day 14; cancer (breast); endocrinology.

P6932 Escartin,C., Boyer,F., Bemelmans,A.P., Hantraye,P., Brouillet,E. Insulin growth factor-I protects against excitotoxicity in the rat striatum. NeuroReport 2004; 15(-14-):2251-2254. >>> Insulin-like growth factor, recomb. human; BSA; acetic acid; CSF/CNS; Rat; 1003D; 2 days; ALZET brain infusion kit; neurodegenerative (Huntington's disease); dental cement used.

P6929 Jevdjovic,T., Maake,C., Eppler,E., Zoidis,E., Reinecke,M., Zapf,J. Effects of insulin-like growth factor-I treatment on the endocrine pancreas of hypophysectomized rats: comparison with growth hormone replacement. European Journal of Endocrinology 2004; 151(-2-):223-231. >>> Insulin-like growth factor, recomb. human; Acetic acid; IP; Rat; 2001; 2 days; Controls received mp w/ vehicle; IGF plasma levels taken; peptides.

P6858 Lopez-Lopez,C., LeRoith,D., Torres-Aleman,I. Insulin-like growth factor I is required for vessel remodeling in the adult brain. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-26-):9833-9838. >>> Insulin-like growth factor I; antibody, anti-IGF I; serum, rabbit; SC; Mice; 2001; 2 weeks; 28 days; Controls received mp w/ saline or serum; comparison of microsphere injections vs. mp.

P6848 Kamegai,J., Tamura,H., Shimizu,T., Ishii,S., Tatsuguchi,A., Sugihara,H., Oikawa,S., Kineman,R.D. The role of pituitary ghrelin in growth hormone (GH) secretion: GH-releasing hormone-dependent regulation of pituitary ghrelin gene expression and peptide content. Endocrinology 2004; 145(-8-):3731-3738. >>> Growth hormone, rat; insulin-like growth factor I, recomb. human; Saline; SC; Rat; 1003D; 72 hours; Controls received mp w/ vehicle; peptides.

P6839 Thordarson,G., Slusher,N., Leong,H., Ochoa,D., Rajkumar,L., Guzman,R., Nandi,S., Talamantes,F. Insulin-like growth factor (IGF)-I obliterates the pregnancy-associated protection against mammary carcinogenesis in rats: evidence that IGF-I enhances cancer progression through estrogen receptor-alpha activation via the mitogen-activated protein kinase pathway. BREAST CANCER RESEARCH 2004; 6(-4-):R423-R436. >>> Insulin-like growth factor I, recomb. human; SC; Rat (pregnant); 60 days; Controls received mp w/ vehicle or no treatment; functionality of mp verified by IGF-I plasma levels; cancer (mammary).

P6838 Thordarson,G., Semaan,S., Low,C., Ochoa,D., Leong,H., Rajkumar,L., Guzman,R.C., Nandi,S., Talamantes,F. Mammary tumorigenesis in growth hormone deficient spontaneous dwarf rats; effects of hormonal treatments. Breast Cancer Research and Treatment 2004; 87(-3-):277-290. >>> Insulin-like growth factor I, recomb. human; SC; Rat; 21 weeks; 10 days; Controls received no treatment; replacement therapy (GH deficient, dwarf); long-term study; cancer (mammary); peptides.

P6835 Cao,W.M., Murao,K., Imachi,H., Yu,X., Dobashi,H., Yoshida,K., Muraoka,T., Kotsuna,N., Nagao,S., Wong,N.C.W., Ishida,T. Insulin-like growth factor-i regulation of hepatic scavenger receptor class BI. Endocrinology 2004; 145(-12-):5540-5547. >>> Insulin-like growth factor I; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by plasma IGF-I concentrations.

P6798 Brussee,V., Cunningham,F.A., Zochodne,D.W. Direct insulin signaling of neurons reverses diabetic neuropathy. Diabetes 2004; 53(-7-):1824-1830. >>> Insulin, human; FITC-Insulin; Insulin-like growth factor I; antibody, polyclonal anti-rat insulin; dye, india ink; antibody, polyclonal anti-albumin; Saline; SC; CSF/CNS (intrathecal); Rat; 2, 4 weeks; Controls received mp w/ vehicle or anti-albumin Ab; functionality of mp verified by dye; replacement therapy (streptozotocin induced diabetes); india ink used to confirm catheter placement and intrathecal delivery.

P6796 Xian,C.J., Howarth,G.S., Cool,J.C., Foster,B.K. Effects of acute 5-fluorouracil chemotherapy and insulin-like growth factor-I pretreatment on growth plate cartilage and metaphyseal bone in rats. Bone 2004; 35(-3-):739-749. >>> Insulin-like growth factor I, recomb. human; Acetic acid; SC; Rat; 7 days; Controls received mp w/ vehicle; cancer; osteoporosis.

P6757 Iikubo,M., Ikeda,H., Kobayashi,A., Kojima,I., Hashimoto,K., Sakamoto,M., Sasano,T. Insulin-like growth factor-I stimulates acromegaly-like specific mandibular enlargement in rats. Hormone and Metabolic Research 2004; 36(-10-):696-701. >>> Insulin-like growth factor I, recomb. human; Saline; SC; Rat; 2002; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by human IGF-I serum levels; peptides.

P6615 Sakata,T., Wang,Y.M., Halloran,B.P., Elalieh,H.Z., Cao,J., Bikle,D.D. Skeletal unloading induces resistance to insulin-like growth factor-I (IGF-I) by inhibiting activation of the IGF-I signaling pathways. Journal of Bone and Mineral Research 2004; 19(-3-):436-446. >>> Insulin-like growth factor; uridine, bromodeoxy-; Sodium succinate; DMSO; propylene glycol; SC; Rat (dwarf); 14 days; BrdU was dissolved in 50% DMSO/50% propylene glycol for labeling of osteocytes; pump model not listed.

P6519 Haddad,F., Adams,G.R. Inhibition of MAP/ERK kinase prevents IGF-I-induced hypertrophy in rat muscles. Journal of Applied Physiology 2004; 96(-1-):203-210. >>> PD-98059; insulin-like growth factor I; IM (plantaris); Rat; 2002; 14 days; Controls received no treatment to the contralateral muscle; functionality of mp verified by residual volume aspiration&measurement; no stress (see pg.205); good methods p. 203; enzyme inhibitor (MAPK/ERK kinase); mp primed in sterile saline @ 37 degrees Celsius.

R0186 Hursting,S.D., Lavigne,J.A., Berrigan,D., Perkins,S.N., Barrett,J.C. Calorie restriction, aging, and cancer prevention: Mechanisms of action and applicability to humans. ANNUAL REVIEW OF MEDICINE-SELECTED TOPICS IN THE CLINICAL SCIENCES 2003; 54(--):131-152. >>> Insulin-like growth factor I, recomb. human-; Saline; Rat; mice; 4 weeks; Controls received mp w/ vehicle.

P6602 Tolbert,D.L., Clark,B.R. GDNF and IGF-I trophic factors delay hereditary Purkinje cell degeneration and the progression of gait ataxia. Experimental Neurology 2003; 183(-1-):205-219. >>> Glial-derived neurotrophic factor; insulin-like growth factor I; SC; Rat; 2004; 4,8 weeks; Controls received mp w/ saline; long-term study; pumps replaced at 4 weeks; peptides.

P6592 Dempsey,R.J., Sailor,K.A., Bowen,K.K., Tuereyen,K., Vemuganti,R. Stroke-induced progenitor cell proliferation in adult spontaneously hypertensive rat brain: effect of exogenous IGF-1 and GDNF. Journal of Neurochemistry 2003; 87(-3-):586-597. >>> Insulin-like growth factor-I; glial-derived neurotrophic factor; CSF, artificial; CSF/CNS; Rat; 1 week; Controls received mp w/ vehicle; ALZET brain infusion kit used; peptides; ischemia (cerebral).

P6510 Moorehead,R.A., Hojilla,C.V., De Belle,I., Wood,G.A., Fata,J.E., Adamson,E.D., Watson,K.L.M., Edwards,D.R., Khokha,R. Insulin-like growth factor-II regulates PTEN expression in the mammary gland. Journal of Biological Chemistry 2003; 278(-50-):50422-50427. >>> Insulin-like growth factor-II, recomb. human; PBS; BSA; IP; Mice; 1002; 14 days; Controls received mp w/ vehicle; comparison of mammary gland injections vs. mp; cancer (breast); peptides.

P6405 Kirk,S.P., Oldham,J.M., Jeanplong,F., Bass,J.J. Insulin-like growth factor-II delays early but enhances late regeneration of skeletal muscle. JOURNAL OF HISTOCHEMISTRY&CYTOCHEMISTRY 2003; 51(-12-):1611-1620. >>> Insulin-like growth factor-II; Acetic acid; culture medium, RPMJ 1640; IM; Rat; 1007D; 7 days; Tissue perfusion (femoris muscle); peptides; IGF-II was recomb. human; vinyl catheter used for IM delivery.

P6221 Hess,B.H., Krewet,J.A., Tolbert,D.L. Olivocerebellar projections are necessary for exogenous trophic factors to delay heredo-Purkinje cell degeneration. Brain Research 2003; 986(-1-2-):54-62. >>> Glial-derived neurotrophic factor; insulin-like growth factor I; CSF/CNS; Rat; 2002; 2 weeks; Controls received mp w/ saline or no treatment; ALZET brain infusion kit used.

P6101 Lupien,S.B., Bluhm,E.J., Ishii,D.N. Systemic insulin-like growth factor-I administration prevents cognitive impairment in diabetic rats, and brain IGF regulates learning/memory in normal adult rats. Journal of Neuroscience Research 2003; 74(-4-):512-523. >>> Insulin-like growth factor; antiserum, human IGF II; serum, preimmune; Acetic acid; CSF, artificial; SC; CSF/CNS; Rat; 7.5 weeks; Pumps replaced every 19 days; ALZET brain infusion kit used; peptides; diabetes; IGF delivered SC and separate study for ICV infusion of anti-IGF-II antiserum or preimmune serum; (PIS) dissolved in aCSF; cannulae placement verified post experiment by bromophenol blue.

P6089 Mejia-Naranjo,W., Yakar,S., Bernal,R., LeRoith,D., Sanchez-Gomez,M. Regulation of the splenic somatotropic axis by dietary protein and insulin-like growth factor-I in the rat. GROWTH HORMONE&IGF RESEARCH 2003; 13(-5-):254-263. >>> Insulin-like growth factor I; Acetic acid; SC; Rat; 2001; 7 days; Controls received mp w/ vehicle; functionality of mp verified by IGF-I plasma levels taken; IGF-I was recomb human and was dissolved in .01M acetic acid.

P5773 Scheinowitz,M., Kessler-Icekson,G., Freimann,S., Zimmermann,R., Schaper,W., Golomb,E., Savion,N., Eldar,M. Short and long-term swimming exercise training increases myocardial insulin-like growth factor-I gene expression. GROWTH HORMONE&IGF RESEARCH 2003; 13(-1-):19-25. >>> Insulin-like growth factor I; Albumin, rat serum; IP; Rat; 2001; 1 week; Controls received mp w/ vehicle; peptides; recomb. Human IgF-1 used.

R0219 Van Den Berg,W.B. Is there a rationale for combined TNF and IL-1 blocking in arthritis?. Clinical and Experimental Rheumatology 2002; 20(-Suppl. 28-):S21-S25. >>> Insulin-like growth factor I, receptor antagonist; Mice; ; "In mice full protection is only achieved with continued dosing in ALZET minipumps." (p. S-24).

R0192 Cardona-Gomez,G.P., Mendez,P., DonCarlos,L.L., Azcoitia,I., Garcia-Segura,L.M. Interactions of estrogen and insulin-like growth factor-I in the brain: molecular mechanisms and functional implications. Journal of Steroid Biochemistry and Molecular Biology 2002; 83(-1-5-):211-217. >>> Insulin-like growth factor I; CSF/CNS; Rat; 1007D; ; Controls received mp w/ vehicle; replacement therapy (ovariectomy); see pg. 214, figure 3.

R0155 Lieberman,J.R., Daluiski,A., Einhorn,T.A. The role of growth factors in the repair of bone - Biology and clinical applications. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME 2002; 84A(--):1032-1044. >>> Insulin-like growth factor-I; Dulbecco's mem; CSF/CNS (sciatic nerve); Rat; 2004; 6 weeks; Controls received mp w/ vehicle; no stress (see pg. 89); animal info (female, wistar, 250-300 g).

P7698 Seurin,D., Lassarre,C., Bienvenu,G., Babajko,S. Insulin-like growth factor binding protein-6 inhibits neuroblastoma cell proliferation and tumour development. Eur.J.Cancer 2002/10; 38(-15-):2058-2065. >>> Insulin-like growth factor binding protein-6; glutathione S-transferase; SC; Mice (nude); 1002; 2 weeks; Controls received mp w/ GST; dose-response (table 1); comparison of daily IP injections vs. mp; cancer (neuroblastoma); peptides; animal info (female, SP Swiss nude, 6 wk old); "The (tumor developed) delay was not evident in mice injected i.p., possibly because IGFBP-6 is rapidly degraded in the bloodstream." (p. 2063).

P6336 Cardona-Gomez,G.P., Mendez,P., Garcia-Segura,L.M. Synergistic interaction of estradiol and insulin-like growth factor-I in the activation of P13K/Akt signaling in the adult rat hypothalamus. MOLECULAR BRAIN RESEARCH 2002; 107(-1-):80-88. >>> Insulin-like growth factor-I; CSF, artificial; CSF/CNS; Rat; 2002; 7 days; Controls received mp w/ vehicle; replacement therapy (ovariectomy); comparison of ICV injections vs. mp; ALZET brain infusion kit used.

P6192 Dunaiski,V., Belford,D.A. Contribution of circulating IGF-I to wound repair in GH-treated rats. GROWTH HORMONE&IGF RESEARCH 2002; 12(-6-):381-387. >>> Insulin-like growth factor I; Acetic acid; IP; Rat; 2001; 7 days; Controls received mp w/ vehicle; stability verified by daily animal weight gain; imunology; peptides.

P5890 Gregorevic,P., Plant,D.R., Leeding,K.S., Bach,L.A., Lynch,G.S. Improved contractile function of the mdx dystrophic mouse diaphragm muscle after insulin-like growth factor-I administration. American Journal of Pathology 2002; 161(-6-):2263-2272. >>> Insulin-like growth factor; HCL; Saline; SC; Mice; 1002; 8 weeks; Functionality of mp verified by residual volume; long-term study; pumps replaced after 2 weeks; no stress (see pg. 2264); good methods p. 2264; muscular dystrophy; partially dipped in paraffin wax to achieve a pumping rate of 0.125 ul/hr for 28 days.

P5602 Carro,E., Trejo,J.L., Gomez-Isla,T., LeRoith,D., Torres-Aleman,I. Serum insulin-like growth factor I regulates brain amyloid-B levels. Nature Medicine 2002; 8(-12-):1390-1397. >>> Insulin-like growth factor I; SC; Mice; Rat; 2004; 1002; 1 month; Peptides; neurodegenerative (Alzheimer's disease); controls received mp w/ saline; functionality of mp verified by serum IGF-1 levels.

P5590 Gevers,E.F., Loveridge,N., Robinson,I.C.A.F. Bone marrow adipocytes: A neglected target tissue for growth hormone. Endocrinology 2002; 143(-10-):4065-4073. >>> Growth hormone; Insulin-like growth factor I; Parathyroid hormone (1-34); BSA; water; SC; rat; 2002; 2 weeks; replacement therapy (genetically GH-deficient rats); peptides.

P5543 Bachelot,A., Monget,P., Imbert-Bollore,P., Coshigano,K., Kopchick,J.J., Kelly,P.A., Binart,N. Growth hormone is required for ovarian follicular growth. Endocrinology 2002; 143(-10-):4104-4112. >>> Insulin-like growth factor; SC; Mice; 2 weeks; Peptides.

P5510 Zoidis,E., Gosteli-Peter,M., Ghirlanda-Keller,C., Meinel,L., Zapf,J., Schmid,C. IGF-I and GH stimulate Phex mRNA expression in lungs and bones and 1,2 5-dihydroxyvitamin D-3 production in hypophysectomized rats. European Journal of Endocrinology 2002; 146(-1-):97-105. >>> Growth hormone; Insulin-like growth factor I; Acetic acid; SC; Rat; 2001; 2 days; Controls received mp w/ vehicle; functionality of mp verified by IGF-I plasma levels; replacement therapy (hypohysectomy); peptides.

P5455 Conover,C.A., Johnstone,E.W., Turner,R.T., Evans,G.L., Ballard,F.J., Doran,P.M., Khosla,S. Subcutaneous administration of insulin-like growth factor (IGF)-II/IGF binding protein-2 complex stimulates bone formation and prevents loss of bone mineral density in a rat model of disuse osteoporosis. GROWTH HORMONE&IGF RESEARCH 2002; 12(-3-):178-183. >>> Insulin-like growth factor II; Insulin-like growth factor II, binding protein; Saline; BSA; SC; Rat; 14 days; Peptides.

P5449 Kita,K., Shibata,T., Yaman,M.A., Nagao,K., Okumura,J. Response of muscle protein synthesis to the infusion of insulin-like growth factor-I and fasting in young chickens. ASIAN-AUSTRALASIAN JOURNAL OF ANIMAL SCIENCES 2002; 15(-12-):1760-1764. >>> Insulin-like growth factor I; Acetic acid; SC; Bird (chicken); 2001D; 1 day; Functionality of mp verified by IGF-I plasma levels; recomb. chicken IGF-I used.

P5430 Wickman,A., Jonsdottir,I.H., Bergstrom,G., Hedin,L. GH and IGF-I regulate the expression of endothelial nitric oxide synthase (eNOS) in cardiovascular tissues of hypophysectomized female rats. European Journal of Endocrinology 2002; 147(-4-):523-533. >>> Insulin-like growth factor I; SC; Rat; 2001; 7 days; Functionality of mp verified by IGF-I plasma levels (table 1, p. 529); replacement therapy (hypophysectomy); cardiovascular.

P5420 Tonner,E., Barber,M.C., Allan,G.J., Beattie,J., Webster,J., Whitelaw,C.B.A., Flint,D.J. Insulin-like growth factor binding protein-5 (IGFBP-5) induces premature cell death in the mammary glands of transgenic mice. Development 2002; 129(-19-):4547-4557. >>> Insulin-like growth factor I analogue; Acetic acid; SC; Mice (transgenic, pregnant); 1002; 14 days; Peptides; IGF-I analogue used was R-3-IGF-I.

P5402 Zapf,J., Gosteli-Peter,M., Weckbecker,G., Hunziker,E.B., Reinecke,M. The somatostatin analog octreotide inhibits GH-stimulated, but not IGF-I-stimulated, bone growth in hypophysectomized rats. Endocrinology 2002; 143(-8-):2944-2952. >>> Insulin-like growth factor I; growth hormone, human; octreotide; Sodium acetate; benzylalcohol; water; SC; Rat; 2001; 6 days; Controls received mp w/ vehicle; functionality of mp verified by IGF-I plasma levels; peptides; recomb. human IGF-I and recomb. human GF used; some animals received 2 pumps: one with octreotide and one with GH.

P5368 Tanaka,H., Wakisaka,A., Ogasa,H., Kawai,S., Liang,C.T. Effect of IGF-I and PDGF administered in vivo on the expression of osteoblast-related genes in old rats. Journal of Endocrinology 2002; 174(-1-):63-70. >>> Insulin-like growth factor I; platelet-derived growth factor; Bone (femoral cavity); Rat; 5 days; Controls received mp w/ vehicle; functionality of mp verified by residual volume; peptides.

P5366 Stabnov,L., Kasukawa,Y., Guo,R., Amaar,Y., Wergedal,J.E., Baylink,D.J., Mohan,S. Effect of insulin-like growth factor-1 (IGF-1) plus alendronate on bone density during puberty in IGF-1-deficient MIDI mice. Bone 2002; 30(-6-):909-916. >>> Insulin-like growth factor I; PBS; SC; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; comparison of 3 daily injections single daily injections and continuous mp infusion; half-life (p. 914) of IGF-I is 10 min.; peptides; animal body wieghts listed (table 1; p. 911).

P5324 Chavez,J.C., LaManna,J.C. Activation of hypoxia-inducible factor-1 in the rat cerebral cortex after transient global ischemia: Potential role of insulin-like growth factor-1. Journal of Neuroscience 2002; 22(-20-):8922-8931. >>> Insulin-like growth factor I; Insulin-like growth factor I, receptor antagonist; PBS; saline;; SC; CSF/CNS; Rat; 1003D; 2001; 4 or 7 days; Functionality of mp verified by IGF-1 plasma levels; peptides; ALZET brain infusion kit used; the IGF-1 receptor antagonist, JB-1, was used; IGF-1 infused (SC of ICV) for 7 days w/ 2001 pumps; JB-1 infused for 4 day via 1003D pumps; ischemia (cardiac).

P5316 Papakonstantinou,K.C., Shiamishis,G., Bates,M., Terzis,J.K. Distraction osteogenesis using IGF-I after nerve microreconstruction. Journal of Reconstructive Microsurgery 2002; 18(-5-):401-410. >>> Insulin-like growth factor I; Saline; SC; Rat; ; Controls received mp w/vehicle; peptides.

P5198 Dunshea,F.R., Chung,C.S., Owens,P.C., Ballard,J.F., Walton,P.E. Insulin-like growth factor-I and analogues increase growth in artificially-reared neonatal pigs. Br.J Nutr. 2002/6; 87(-6-):587-593. >>> Insulin-like growth factor I; Insulin-like growth factor I, LR3-; Acetic acid; SC; Pig (neonate); 2001; 8,9 or 18 days; Controls received mp w/ vehicle; functionality verified by plasma levels; pumps replaced after 8 or 9 days; peptides;.

P5137 Jager,D., Muller-Werdan,U., Ponicke,K., Holtz,J., Werdan,K., Muller,S.P. The impact of insulin-like growth factor-1 on the pattern of cardiac elongation factor-2 variants in a model of overload. MOLECULAR AND CELLULAR BIOCHEMISTRY 2002; 229(--):25-34. >>> Insulin-like Growth Factor I; Saline; SC; rat; 12 days; controls received mp w/ vehicle; cardiovascular; peptides.

P5065 Tanaka,H, Wakisaka,A, Ogasa,H, Kawai,S. Effect of IGF-1 and PDGF administered in vivo on the Expression of Osteoblast-related Genes in Old Rats. Journal of Endocrinology 2002; 174(--):63-70. >>> Platelet-derived growth factor; Insulin-like growth factor I; SC; bone (femur); rat; 5 days; controls received mp w/ vehicle; tissue perfusion (bone); functionality of mp verified by residual aspiration (p. 64); peptides; growth factors were human recombinant; agents infused separately or concomitantly;.

top of page

5. Nerve Growth Factor

P7978 Engelhardt,M., Di Cristo,G., Berardi,N., Maffei,L., Wahle,P. Differential effects of NT-4, NGF and BDNF on development of neurochemical architecture and cell size regulation in rat visual cortex during the critical period. European Journal of Neuroscience 2007; 25(-2-):529-540. >>> Nerve growth factor, mouse; NT-4, human recomb.; brain-derived neurotrophic factor, recomb. human; CSF/CNS (visual cortex); Rat; 1007D; 8 days; Post op. care (antibiotics and local anesthetics); animal info (Long-Evans); dental cement used; 30 G cannula used; tissue perfusion (visual cortex).

P8023 Niewiadomska,G., Baksalerska-Pazera,M., Gasiorowska,A., Mietelska,A. Nerve growth factor differentially affects spatial and recognition memory in aged rats. Neurochemical Research 2006; 31(-12-):1481-1490. >>> Nerve growth factor, beta; CSF, artificial; CSF/CNS; Rat; 2004; 1 month; ALZET brain infusion kit used; post op. care (antibiotic and analgesic to scalp + fluid therapy); silastic tubing used; 28 G cannula.

P7728 Frielingsdorf,H., Thal,L.J., Pizzo,D.P. The septohippocampal cholinergic system and spatial working memory in the Morris water maze. Behavioural Brain Research 2006; 168(-1-):37-46. >>> Nerve growth factor, recomb. human; CSF, artificial; gentamicin; albumin, rat serum; CSF/CNS; Rat; 2004; 4 weeks; Controls received mp w/ vehicle; functionality of mp verified by residual volume; cannula placement confirmed by cresyl violet staining; peptides; animal info (male, Fisher 344, 13-14 wk. old, medial septum lesion, 400g); mp primed 2 days in 37 Celsius saline.

P7582 Cardoso,A., Paula-Barbosa,M.M., Lukoyanov,N.V. Reduced density of neuropeptide Y neurons in the somatosensory cortex of old male and female rats: Relation to cholinergic depletion and recovery after nerve growth factor treatment. Neuroscience 2006; 137(-3-):937-948. >>> Dye, methylene blue; nerve growth factor; CSF, artificial; BSA; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle or sham surgery; functionality of mp verified by pretesting; Alzet brain infusion kit used; post op. care (antiseptic); animal info (male, female, Wistar 6 month old, 24 month old); Lynch coil filled with NGF, air-oil spacer between mp and catheter, mp filled with dye.

P7365 Jakubowska-Dogru,E., Guemuesbas,U. Chronic intracerebroventricular NGF administration improves working memory in young adult memory deficient rats. Neuroscience Letters 2005; 382(-1-2-):45-50. >>> Nerve growth factor, recomb. rat; CSF, artificial; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; memory; behavioral study.

P7289 Pereira,P.A., Cardoso,A., Paula-Barbosa,M.M. Nerve growth factor restores the expression of vasopressin and vasoactive intestinal polypeptide in the suprachiasmatic nucleus of aged rats. Brain Research 2005; 1048(-1-2-):123-130. >>> Nerve growth factor; dye, methylene blue; CSF/CNS; Rat; 2002; 14 days; Functionality of mp verified by pretesting delivery rate; ALZET brain infusion kit used; peptides; post op. care (SC saline, local antiseptic); mp filled with Methylene blue, air-oil spacer at tubing connection, tubing filled with NGF; Lynch coil; "Because there is evidence that the surgical procedure does not interfere with the structure of SCN, vehicle - treated rats were not included in this study." (p. 124).

P7244 Obata,K., Katsura,H., Mizushima,T., Yamanaka,H., Kobayashi,K., Dai,Y., Fukuoka,T., Tokunaga,A., Tominaga,M., Noguchi,K. TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury. Journal of Clinical Investigation 2005; 115(-9-):2393-2401. >>> SB203580; antibody, anti-nerve growth factor; oligodeoxynucleotide, antisense; oligodeoxynucleotide, FITC antisense; oligodeoxynucleotide, missense; DMSO; saline; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle, or sham surgery or mismatch ODN or contralateral no treatment; antisense (TRPA1); brain tissue distribution; 50% DMSO.

P7008 DeKosky,S.T., Abrahamson,E.E., Taffe,K.M., Dixon,C.E., Kochanek,P.M., Ikonomovic,M.D. Effects of post-injury hypothermia and nerve growth factor infusion on antioxidant enzyme activity in the rat: implications for clinical therapies. Journal of Neurochemistry 2004; 90(-4-):998-1004. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2002; 1,3 days; Controls received mp w/ vehicle; stability verified by increased ChAT activity.

P6996 Bruno,M.A., Clarke,P.B.S., Seltzer,A., Quirion,R.M., Burgess,K., Cuello,A.C., Saragovi,H.U. Long-lasting rescue of age-associated deficits in cognition and the CNS cholinergic phenotype by a partial agonist peptidomimetic ligand of TrkA. Journal of Neuroscience 2004; 24(-37-):8009-8018. >>> Nerve growth factor; D3; dye, methylene blue; CSF, artificial, buffered; saline; CSF/CNS; Rat; 2002; 14 days; Controls received mp w/ vehicle; functionality of mp verified by infusion volume (pg. 8011); no stress (see pg. 8012); ALZET brain infusion kit used; peptides; used air-oil spacer in PE tubing at pump end, PE tubing used in coil for D3 mp filled with dye; D3 is a peptidomimetic which binds TrKA.

P6930 Gillespie,L.N., Clark,G.M., Marzella,P.L. Delayed neurotrophin treatment supports auditory neuron survival in deaf guinea pigs. NeuroReport 2004; 15(-7-):1121-1125. >>> Brain-derived neurotrophic factor; nerve growth factor; NT-3; NT-4/5; Ear (scala tympani, cochlea); Guinea-pig; 2004; 28 days; Tissue perfusion.

P6922 Chen,J.R., Wang,Y.J., Tseng,G.F. The effects of decompression and exogenous NGF on compressed cerebral cortex. Journal of Neurotrauma 2004; 21(-11-):1640-1651. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2ML2; 14 days; Used coiled PE tubing (Lynch coil).

P6761 McCallister,W.V., McCallister,E.L., Dubois,B., Trumble,T.E. Regeneration along intact nerves using nerve growth factor and ciliary neurotrophic factor. Journal of Reconstructive Microsurgery 2004; 20(-6-):473-481. >>> Nerve growth factor; ciliary neurotrophic factor; CSF/CNS (peroneal nerve); Rat; 2ML4; 28 days; Controls received mp w/ isotonic saline; peptides; mp primed 24 hours in 37 degrees Celsius saline.

P6451 Seki,S., Sasaki,K., Igawa,Y., Nishizawa,O., Chancellor,M.B., De Groat,W.C., Yoshimura,N. Suppression of detrusor-sphincter dyssynergia by immunoneutralization of nerve growth factor in lumbosacral spinal cord in spinal cord injured rats. Journal of Urology 2004; 171(-1-):478-482. >>> Antibody, anti-nerve growth factor; CSF, artificial; CSF/CNS (intrathecal); Rat; 2002; 14 days; Controls received mp w/ vehicle; spinal cord injury; PE-10 used for catheterization.

P6354 Harrington,A.W., Leiner,B., Blechschmitt,C., Arevalo,J.C., Lee,R., Moerl,L., Meyer,M., Hempstead,B.L., Yoon,S.O., Giehl,K.M. Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2004; 101(-16-):6226-6230. >>> Antibody, anti-nerve growth factor, neutralizing mouse; serum; immunoglobulin-G; penicillin; streptomycin; PBS; CSF/CNS (cortex); Rat; 2001; 1 week; Controls received mp w/ vehicle.

P6706 Paula-Barbosa,M.M., Pereira,P.A., Cadete-Leite,A., Madeira,M.D. NGF and NT-3 exert differential effects on the expression of neuropeptides in the suprachiasmatic nucleus of rats withdrawn from ethanol treatment. Brain Research 2003; 983(-1-2-):64-73. >>> Nerve growth factor; NT-3; CSF, artificial; BSA; CSF/CNS; Rat; 2002; 10 days; Controls received mp w/ vehicle; ALZET brain infusion kit used; dependence; post op. care (local antiseptic); agent was placed in catheter, tubing had an air-oil spacer at pump end, mp contained methylene blue (p.66).

P6679 Castellanos,M.R., Aguiar,J., Fernandez,C.I., Almaguer,W., Mejias,C., Varela,A. Evaluation of the neurorestorative effects of the murine beta-nerve growth factor infusions in old rat with cognitive deficit. Biochemical and Biophysical Research Communications 2003; 312(-4-):867-872. >>> Nerve growth factor, beta, murine; Saline; CSF/CNS (parenchyma); CSF/CNS; Rat; 2002; 2 weeks; Comparison of ICV infusion vs. intraparenchymal infusion.

P6075 Cahill,C.M., Dray,A., Coderre,T.J. Intrathecal nerve growth factor restores opioid effectiveness in an animal model of neuropathic pain. Neuropharmacology 2003; 45(-4-):543-552. >>> Nerve growth factor; CSF, artificial; CSF/CNS (intrathecal); Rat; 2001; 7 days; Controls received mp w/ vehicle; IT catheter was PE-10 to PE-60; behavioral testing.

P6065 DeCouto,S.A., Jones,E.E., Kudwa,A.E., Shoemaker,S.E., Shafer,A.J., Brieschke,M.A., James,R., Vaughn,J.C., Isaacson,L.G. The effects of deafferentation and exogenous NGF on neurotrophins and neurotrophin receptor mRNA expression in the adult superior cervical ganglion. MOLECULAR BRAIN RESEARCH 2003; 119(-1-):73-82. >>> Cytochrome C; nerve growth factor; Acetic acid; bisbenzimide; CSF/CNS; Rat; 2002; 2 weeks; Functionality of mp verified by labeling of the ependymyl lining of the lateral and 3rd ventricles with 0.1% bisbenzimide; post op. care (acetaminophen suspension drops (80mg/day) in a cheese puff); 0.05 acetic acid used for vehicle.

P5993 Lukoyanov,N.V., Pereira,P.A., Paula-Barbosa,M.M., Cadete-Leite,A. Nerve growth factor improves spatial learning and restores hippocampal cholinergic fibers in rats withdrawn from chronic treatment with ethanol. Experimental Brain Research 2003; 148(-1-):88-94. >>> Nerve growth factor; CSF, artificial; CSF/CNS; Rat; 2004; 28 days; Controls received mp w/ vehicle; peptides; behavioral study.

P5968 Melchior,B., Nerriere-Daguin,V., Laplaud,D.A., Remy,S., Wiertlewski,S., Neveu,I., Naveilhan,P., Meakin,S.O., Brachet,P. Ectopic expression of the TrkA receptor in adult dopaminergic mesencephalic neurons promotes retrograde axonal NGF transport and NGF-dependent neuroprotection. Experimental Neurology 2003; 183(-2-):367-378. >>> Nerve growth factor; Saline; Sodium bicarbonate; potassium chloride; KH2; P04; calcium chloride; magnesium chloride; sodium sulfate; glucose; CSF/CNS; Rat; 2002; 2 weeks; Controls received mp w/ vehicle; peptides; neurodegenerative (Alzheimer's disease, Parkinson's disease); NGF was recomb. human.

P5965 Cadete-Leite,A., Pereira,P.A., Madeira,M.D., Paula-Barbosa,M.M. Nerve growth factor prevents cell death and induces hypertrophy of basil forebrain cholinergic neurons in rats withdrawn from prolonged ethanol intake. Neuroscience 2003; 119(-4-):1055-1069. >>> Nerve growth factor; dye, methylene blue; CSF; BSA; CSF/CNS; Rat; 2004; 28 days; good methods p. 1057; ALZET brain infusion kit 1 used; peptides; post op. care (sc injection of saline and cortrimoxazol); lynch coil used; air bubble used to separate vehicle and agent/vehicle; pump contained dye.

P5632 Wahle,P., Di Cristo,G., Schwerdtfeger,G., Engelhardt,M., Berardi,N., Maffei,L. Differential effects of cortical neurotrophic factors on development of lateral geniculate nucleus and superior colliculus neurons: anterograde and retrograde actions. Development 2003; 130(-3-):611-622. >>> Nerve growth factor; NT-4/5; brainderived neurotrophic factor; leukemia inhibitory factor; CSF/CNS (visual cortex); Rat; 1007D; 7 days; Controls received mp w/ cytochrome C; peptides..

P3678 Krenz,N.R., Meakin,S.O., Krassioukov,A.V., Weaver,L.C. Neutralizing intraspinal nerve growth factor blocks autonomic dysreflexia caused by spinal cord injury. J Neurosci 2003; 19(-17-):7405-7414. >>> Antibody, anti-nerve growth factor; Antibody, Immunoglobulin G; CSF, artificial; CSF/CNS (intrathecal); knee (articular cavity); Rat; 2ML2; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified by residual volume; spinal cord injury; PE-10 intrathecal catheter tubing was perforated along its length and tip was sealed; PE-100 catheter used for knee joint infusion.

R0174 Ray,S.K., Dixon,C.E., Banik,N.L. Molecular mechanisms in the pathogenesis of traumatic brain injury. Histology and Histopathology 2002; 17(-4-):1137-1152. >>> Nerve growth factor; ; Peptides; "However, delivery of NGF into the brain is difficult because the active, beta component of the molecule is large and polar, and cannot cross the blood-brain barrier. By use of intracerebroventricular infusions or intermitent injections, NGF was successfully delivered into the CSF of rodents." (p. 51-52); neurodegenerative.

P6637 Van der Zee,C.E.E.M., Hagg,T. Delayed NGF Infusion Fails to Reverse Axotomy-Induced Degeneration of Basal Forebrain Cholinergic Neurons In Adult P75LNTR-Deficient Mice. Neuroscience 2002; 110(-4-):641-651. >>> Nerve growth factor-beta; CSF/CNS (ipsilateral septum); Mice; 1007D; 7 days; Controls received mp w/ vehicle; peptides.

P6243 Viegi,A., Cotrufo,T., Berardi,N., Mascia,L., Maffei,L. Effects of dark rearing on phosphorylation of neurotrophin Trk receptors. European Journal of Neuroscience 2002; 16(-10-):1925-1930. >>> Nerve growth factor; brain-derived neurotrophic factor, recomb. human; NT-4; CSF/CNS (visual cortex); Rat; 8 days; Controls received mp w/ cytochrome c; peptides.

P6220 Pizzo,D.P., Winkler,J., Sidiqi,I., Waite,J.J., Thal,L.J. Modulation of sensory inputs and ectopic presence of Schwann cells depend upon the route and duration of nerve growth factor administration. Experimental Neurology 2002; 178(-1-):91-103. >>> Nerve growth factor, recomb. human; cytochrome c; PBS; CSF/CNS; CSF/CNS (nucleus basalis magnocellularis); Rat; 2004; 3,6 months; Controls received mp w/ vehicle; long-term study; pumps replaced every 4 weeks; stress/adverse reaction: (see pg. 98) minor inflammatory response at cannulation site; brain tissue distribution; peptides.

P5870 Shoemaker,S.E., Kudwa,A.E., Isaacson,L.G. Sympathetic in growth to the trigeminal ganglion following intracerebroventricular infusion of nerve growth factor. Brain Research 2002; 956(-1-):136-148. >>> Nerve growth factor; Cytochrome C; Acetic acid; CSF/CNS; Rat; 2002; 2 weeks; Controls received mp w/ vehicle; functionality of mp verified; peptides; "accuracy of pump placement was monitored by inclusion of 0.1% bisbenzimide in the infusate&visualization of fluorescence of the ependymal venticular lining" (p. 138).

P5588 Leffler,A., Cummins,T.R., Dib-Hajj,S.D., Hormuzdiar,W.N., Black,J.A., Waxman,S.G. GDNF and NGF reverse changes in repriming of TTX-sensitive Na+ currents following axotomy of dorsal root ganglion neurons. Journal of Neurophysiology 2002; 88(-2-):650-658. >>> Glial-derived neurotrophic factor; Nerve growth factor; Saline; CSF/CNS (intrathecal, lumbar); rat; 7 days; controls received mp with vehicle; peptides; some animals received both agents infused simultaneously by the same pump; delivery was to the lumbar enlargement.

P5494 Hirata,A., Masaki,T., Motoyoshi,K., Kamakura,K. Intrathecal administration of nerve growth factor delays GAP 43 expression and early phase regeneration of adult rat peripheral nerve. Brain Research 2002; 944(-1-2-):146-156. >>> Nerve growth factor; CSF, artificial; CSF/CNS (intrathecal); Rat; 2002; 3-11days; Controls received mp w/ vehicle; peptides.

P5477 Shoemaker,S.E., Isaacson,L.G. Evidence that nerve growth factor mediates the formation of sensory pericellular baskets in the rat trigeminal ganglion. Neuroscience Letters 2002; 331(-3-):183-187. >>> Nerve growth factor; cytochrome C; Bisbenzimide; CSF/CNS; Rat; 2002; 2 weeks; Functionality of mp verified by residual volume and addition of bisbenzimide in vehicle. Fluorescence of the ependymal lining of the ventricular system indicated successful delivery.

P5469 Seki,S., Sasaki,K., Fraser,M.O., Igawa,Y., Nishizawa,O., Chancellor,M.B., De Groat,W.C., Yoshimura,N. Immunoneutralization of nerve growth factor in the lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. Journal of Urology 2002; 168(-5-):2269-2274. >>> Antibody, anti-nerve growth factor; CSF, artificial; CSF/CNS (intrathecal); Rat; 2002; 11-14 days; Controls received mp w/ vehicle; peptides.

P5456 Kudwa,A.E., Shoemaker,S.E., Crutcher,K.A., Isaacson,L.G. Evidence for reduced accumulation of exogenous neurotrophin by aged sympathetic neurons. Brain Research 2002; 948(-1-2-):24-32. >>> Nerve growth factor; cytochrome C; Acetic acid; bisbenzimide; CSF/CNS; Rat; 2002; 2 weeks; Peptides; bisbenzimide is a fluorescent marker.

P5395 Karchewski,L.A., Gratto,K.A., Wetmore,C., Verge,V.M.K. Dynamic patterns of BDNF expression in injured sensory neurons: differential modulation by NGF and NT-3. European Journal of Neuroscience 2002; 16(-8-):1449-1462. >>> Nerve growth factor; NT-3; PBS; albumin, rat serum; streptomycin; penicillin; CSF/CNS (intrathecal); Rat; 7 days; Mouse B-NGF and human recomb. NT-3 used.

P5265 Rossi,F.M., Sala,R., Maffei,L. Expression of the nerve growth factor receptors TrkA and p75NTR in the visual cortex of the rat: development and regulation by the cholinergic input. J Neurosci. 2002/2/1; 22(-3-):912-919. >>> Nerve growth factor; Cytochrome C; Saline; CSF/CNS (visual cortex); Rat; 1007D; 7 days; Peptides; One group of animals implanted w/ 2 pumps (one containing NGF, one containing Cytochrome C).

top of page

6. Placental Growth Factor

P6669 Tamarat,R., Silvestre,J.S., Ricousse-Roussanne,S., Barateau,V., Lecomte-Raclet,L., Clergue,M., Duriez,M., Tobelem,G., Levy,B.I. Impairment in ischemia-induced neovascularization in diabetes - Bone marrow mononuclear cell dysfunction and therapeutic potential of placenta growth factor treatment. American Journal of Pathology 2004; 164(-2-):457-466. >>> Placental growth factor; SC; Mice; 2001; 14 days; Diabetes, placenta growth factor (PIGF) is a VEGF homologue; ischemia.

P5645 Pipp,F., Heil,M., Issbrucker,K., Ziegelhoeffer,T., Martin,S., van den Heuvel,J., Weich,H., Fernandez,B., Golomb,G., Carmeliet,P., Schaper,W., Clauss,M. VEGFR-1-selective VEGF homologue PlGF is arteriogenic - Evidence for a monocyte-mediated mechanism. Circulation Research 2003; 92(-4-):378-385. >>> Vascular endothelial growth factor; Vascular endothelial growth factor-E; Monocyte chemoattractant protein-1; Placental growth factor; Phosphate buffer; albumin; IA (femoral); Mice; rabbit; 1 week; Controls received mp w/ vehicle; dose-response (p.381); peptides; placenta growth factor (PlGF) is a VEGF homologue; VEGF-E is a chimera containing the heparin-binding domain of VEGF; MCP-1.

top of page

7. Transforming Growth Factor

P7353 Snodgrass-Belt,P., Gilbert,J.L., Davis,F.C. Central administration of transforming growth factor-alpha and neuregulin-1 suppress active behaviors and cause weight loss in hamsters. Brain Research 2005; 1038(-2-):171-182. >>> Transforming growth factor-alpha; BSA; acetic acid; CSF, artificial; CSF/CNS (third ventricle); Hamster; 2002; 16-20 days; Circadian; plastics one cannula; cannula/tubing were filled with aCSF to allow for a 48 delay; behavioral study.

P7136 Bandyopadhyay,A., Wang,L., Loepz-Casillas,F., Mendoza,V., Yeh,I.T., Sun,L.Z. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. PROSTATE 2005; 63(-1-):81-90. >>> Transforming growth factor-B3 receptor, recomb. soluble; PBS; SC; Mice (nude); 2002; 14 days; Controls received mp w/ vehicle; comparison of IP injections vs. mp; no stress (see pg. 84,88); cancer (prostate); multiple pumps per animal (2).

P7068 Harris-White,M.E., Balverde,Z., Lim,G.P., Kim,P., Miller,S.A., Hammer,H. Role of LRP in TGFbeta2-mediated neuronal uptake of A beta and effects on memory. Journal of Neuroscience Research 2004; 77(-2-):217-228. >>> Amyloid protein, beta; transforming growth factor-B2; receptor-associated protein; HEPES buffer; CSF/CNS; Mice; 1002; 2 weeks; Controls received mp w/ vehicle; stability verified by incubation at 37 degree Celsius for 2,4 weeks; peptides; RAP is a LRP (lipoprotein receptor-related protein) antagonist; memory.

P6205 Guo,H.L., Epperly,M.W., Bernarding,M., Nie,S.H., Gretton,J., Jefferson,M., Greenberger,J.S. Manganese superoxide dismutase-plasmid/liposome (MnSOD-PL) intratracheal gene therapy reduction of irradiation-induced inflammatory cytokines does not protect orthotopic Lewis Lung Carcinomas. In Vivo 2003; 17(-1-):13-21. >>> Tumor necrosis factor-alpha; transforming growth factor-beta; interleukin-1; Saline, normal; SC; Mice; 1007D; 7 days; Controls received mp w/ vehicle; no stress (see pg. 17); cancer (lung).

P6033 Boengler,K., Pipp,F., Fernandez,B., Ziegelhoeffer,T., Schaper,W., Deindl,E. Arteriogenesis is associated with an induction of the cardiac ankyrin repeat protein (carp). Cardiovascular Research 2003; 59(-3-):573-581. >>> Monocyte chemoattractant protein-1; doxorubicin; transforming growth factor-B1; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular.

P5729 Boengler,K., Pipp,F., Fernandez,B., Richter,A., Schaper,W., Deindl,E. The ankyrin repeat containing SOCS box protein 5: a novel protein associated with arteriogenesis. Biochemical and Biophysical Research Communications 2003; 302(-1-):17-22. >>> Monocyte chemoattractant protein-1; Transforming Growth Factor-B; Doxorubicin; IA (femoral); Rabbit; 2ML1; 24 hours; Cardiovascular; peptides; MCP-1 is monocyte chemoattractant protein 1.

R0155 Lieberman,J.R., Daluiski,A., Einhorn,T.A. The role of growth factors in the repair of bone - Biology and clinical applications. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME 2002; 84A(--):1032-1044. >>> Transforming Growth Factor-B2, soluble receptor; Polymyxin B; IP; mice; 1007D; 2002; 6 weeks; Arthritis; controls received empty pumps or mp w/ vehicle; functionality of mp verified by residual aspiration; pumps replaced after 14 days; stability verified by ELISA after infusion (p. 508, 510); soluble TGF-B RII selectively inhibits transforming growth factor-B; peptides; polymyxin B included as endotoxin inhibitor; 2002 pumps used for 7 and 14 day administration, 21-day group received a 1007D pump for final 7 days.

top of page

8. Vascular Endothelial Growth Factor

P8366 Dorrell,M.I., Aguilar,E., Scheppke,L., Barnett,F.H., Friedlander,M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-3-):967-972. >>> Vascular endothelial growth factor, aptamer; EMD472523; T2-TrpRS; PBS; CSF/CNS (intratumoral); Rat; 2001D; 2ML2; 2ML4; 3, 6 days; 24 hours; Controls received mp w/ vehicle; cancer (gliosarcoma); animal info (male, Fischer, 344); EMD472523 is an integrin antagonist, VEGF aptamer is chemically identical to Macugen; T2 is a proteolytic fragment of tryptophan tRNA synthetase; all agents have angiostatic activity.

P8306 Tiranathanagul,K., Dhawan,V., Lytle,I.F., Zhang,W., Borschel,G.H., Buffington,D.A., Tziampazis,E., Brown,D.L., Humes,H.D. Tissue engineering of an implantable bioartificial hemofilter. ASAIO Journal 2007; 53(-2-):176-186. >>> Platelet-derived growth factor-BB; vascular endothelial growth factor 164; Saline, normal; albumin, rat serum; acetic acid; IA (femoral); IV (femoral); Rat; 2004; 28 days; Artificial kidney; controls received mp w/ vehicle; peptides; animal info (male, Fisher 344); mp attached by cannula to bioartificial hemofilter device, which surrounded and delivered agent to the femoral vessels; nephrology.

P8299 Cruze,C.A., Su,F., Limberg,B.J., Deutsch,A.J., Stoffolano,P.J., Dai,H.J., Buchanan,D.D., Yang,H.T., Terjung,R.L., Spruell,R.D., Mittelstadt,S.W., Rosenbaum,J.S. The Y2 receptor mediates increases in collateral-dependent blood flow in a model of peripheral arterial insufficiency. Peptides 2007; 28(-2-):269-280. >>> Peptide YY, recomb. human; peptide YY (3-36), recomb. human; vascular endothelial growth factor 165; PBS; glycerol; sodium citrate; tween 20; IA (iliac); Rat; 14 days; Controls received mp w/ vehicle; replacement therapy (femoral artery occlusion); dose-response (fig. 4); half-lfie (p. 276)<30 minutes; cardiovascular; peptides; ischemia (hindlimb); animal info (male, Sprague-Dawley, 325-350 grams).

P8267 Warner-Schmidt,J.L., Duman,R.S. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 2007; 104(-11-):4647-4652. >>> Vascular endothelial growth Factor 164, recomb. rat; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; peptides; animal info (male, Sprague-Dawley, 175-200g.).

P8163 Boodhwani,M., Mieno,S., Voisine,P., Feng,J., Sodha,N., Li,J., Sellke,F.W. High-dose atorvastatin is associated with impaired myocardial angiogenesis in response to vascular endothelial growth factor in hypercholesterolemic swine. Journal of Thoracic and Cardiovascular Surgery 2006; 132(-6-):1299-1306. >>> Vascular endothelial growth factor 165, recomb. human; Heparin; Perivascular (circumflex coronary artery); Mini-pig; 2ML4; 4 weeks; Cardiovascular; peptides; ischemia (cardiac); animal info (male, female, yucatan, 20-30 kg, 23 weeks old).

P8017 Kawai,T., Takagi,N., Mochizuki,N., Besshoh,S., Sakanishi,K., Nakahara,M., Takeo,S. Inhibitor of vascular endothelial growth factor receptor tyrosine kinase attenuates cellular proliferation and differentiation to mature neurons in the hippocampal dentate gyrus after transient forebrain ischemia in the adult rat. Neuroscience 2006; 141(-3-):1209-1216. >>> Vascular endothelial growth factor receptor tyrosine kinase inhibitor; DMSO; CSF/CNS (dentate gyrus); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose-response (fig. 4); enzyme inhibitor (VEGF receptor tyrosine kinase); ischemia (transient forebrain); animal info (male, Wistar, 8 weeks old, carotid artery occlusion); 0.5% DMSO; agent also known as 4-[(4'-chloro-2'-fluoro) phenylamino]-6,7-dimethoxyquinazoline; tissue perfusion (dentate gyrus).

P7987 Wang,Y.M., Galvan,V., Gorostiza,O., Ataie,M., Jin,K.L., Greenberg,D.A. Vascular endothelial growth factor improves recovery of sensorimotor and cognitive deficits after focal cerebral ischemia in the rat. Brain Research 2006; 1115(--):186-193. >>> Vascular endothelial growth factor; CSF, artificial; CSF/CNS; Rat; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); behavioral study.

P7784 Gaudio,E., Barbaro,B., Alvaro,D., Glaser,S., Francis,H., Ueno,Y., Meininger,C.J., Franchitto,A., Onori,P., Marzioni,M., Taffetani,S., Fava,G., Stoica,G., Venter,J., Reichenbach,R., De Morrow,S., Summers,R., Alpini,G. Vascular endothelial growth factor stimulates rat cholangiocyte proliferation via an autocrine mechanism. Gastroenterology 2006; 130(-4-):1270-1282. >>> Vascular endothelial growth factor-A, recomb. mouse; vascular endothelial growth factor-C, recomb. mouse; Saline; BSA; IP; Rat; 1 week; Controls received mp w/ vehicle; peptides; animal info (male, Fischer 344, 150-175g.).

P7731 Carr,A.N., Howard,B.W., Yang,H.T., Eby-Wilkens,E., Loos,P., Varbanov,A., Qu,A., DeMuth,J.P., Davis,M.G., Proia,A., Terjung,R.L., Peters,K.G. Efficacy of systemic administration of SDF-1 in a model of vascular insufficiency: Support for an endothelium-dependent mechanism. Cardiovascular Research 2006; 69(-4-):925-935. >>> Vascular endothelial growth factor; stromal cell-derived factor-1a; PBS; glycerol; sodium acetate; sodium azide; IA (iliac); Rat; 2 weeks; Controls received mp w/ vehicle; dose-response (table 1); cardiovascular; peptides; animal info (adult); bilateral femoral artery ligation; occlusive cardiovascular disease.

P7561 Sun,Y.J., Jin,K.L., Childs,J.T., Xie,L., Mao,X.O., Greenberg,D.A. Vascular endothelial growth factor-B (VEGFB) stimulates neurogenesis: Evidence from knockout mice and growth factor administration. Developmental Biology 2006; 289(-2-):329-335. >>> Vascular endothelial growth factor-B; CSF, artificial; CSF/CNS; Rat; mice; 1003D; 3 days; Controls received mp w/ vehicle; ischemia (cerebral); animal info (mice, 10-12 wk old; male, Sprague-Dawley).

P7495 Burchardt,M., Burchardt,T., Anastasiadis,A.G., Buttyan,R., de la Taille,A., Shabsigh,A., Frank,J., Shabsigh,R. Application of angiogenic factors for therapy of erectile dysfunction: protein and DNA transfer of VEGF 165 into the rat penis. UROLOGY 2005; 66(-3-):665-670. >>> Vascular endothelial growth factor, human 165; Saline, sterile; heparin; IA (renal); Rat; 2004; 28 days; Controls received mp w/ vehicle; functionality of mp verified by VEGF serum immunoassay; comparison of CDNA plasmid micro-injections vs. mp; gene therapy; peptides; animal info (male, Sprague-Dawley); urology; 2000 Units of heparin used.

P7417 Schmidt,N.O., Przylecki,W., Yang,W., Ziu,M., Teng,Y., Kim,S.U., Black,P.M., Aboody,K.S., Carroll,R.S. Brain tumor tropism of transplanted human neural stem cells is induced by vascular endothelial growth factor. NEOPLASIA 2005; 7(-6-):623-629. >>> Vascular endothelial growth factor, recomb. human; CSF/CNS (parenchyma); Mice; 2004; ; Controls received mp w/ PBS; functionality of mp verified by residual volume; cancer.

P6908 Alonso,G., Galibert,E., Duvoid-Guillou,A., Vincent,A. Hyperosmotic stimulus induces reversible angiogenesis within the hypothalamic magnocellular nuclei of the adult rat: a potential role for neuronal vascular endothelial growth factor. BMC NEUROSCIENCE 2005; 6(--):U1-U19. >>> Antibody, anti-vascular endothelial growth factor; PBS; CSF/CNS (supraoptic nucleus); Rat; 1007D; 6 days; Schematic fig 9; 10 mm, 26 gauge cannula used.

P6730 Storkebaum,E., Lambrechts,D., Dewerchin,M., Moreno-Murciano,M.P., Appelmans,S., Oh,H., Van Damme,P., Rutten,B., Man,W.Y., De Mol,M., Wyns,S., Manka,D., Vermeulen,K., Van den Bosch,L., Mertens,N., Schmitz,C., Robberecht,W., Conway,E.M., Collen,D., Moons,L., Carmeliet,P., Carmeliet,P. Treatment of motoneuron degeneration by intracerebroventricular delivery of VEGF in a rat model of ALS. Nature Neuroscience 2005; 8(-1-):85-92. >>> Vascular endothelial growth factor, recomb. rat; CSF/CNS; Rat; 2004; 100 days; Long-term study; pumps replaced every 28 days; ALZET brain infusion kit used; VEGF was cleared from CSF within 3h; "70-80% of VEGF in pumps remained active after 4 weeks."; neurodegenerative (Amyotrophic Lateral Sclerosis).

P6634 Croll,S.D., Ransohoff,R.M., Cai,N., Zhang,Q., Martin,F.J., Wei,T., Kasselman,L.J., Kintner,J., Murphy,A.J., Yancopoulos,G.D., Wiegand,S.J. VEGF-mediated inflammation precedes angiogenesis in adult brain. Experimental Neurology 2004; 187(-2-):388-402. >>> Vascular endothelial growth factor 164, mouse; Flt-Fc; angiopoietin I, human; angiopoietin II, human; PBS; CSF/CNS (frontoparietal cortex); Rat; 2002; 1,2,3,4,5,7 days; Controls received mp w/ vehicle or hFc; dose-response (fig. 1); brain tissue distribution; peptides; cyanoacrylate adhesive (Loctite 495).

P6614 Kodama,I., Niida,S., Sanada,M., Yoshiko,Y., Tsuda,M., Maeda,N., Ohama,K. Estrogen regulates the production of VEGF for osteoclast formation and activity in op/op mice. Journal of Bone and Mineral Research 2004; 19(-2-):200-206. >>> Antibody, anti-vascular endothelial growth factor; vascular endothelial growth factor; Flt-1/Fe chimera; SC; Mice; 1002; 2 weeks; Plasma levels taken.

P6564 Suzuki,O., Bishop,A.T., Sunagawa,T., Katsube,K., Friedrich,P.F. VEGF-promoted surgical angiogenesis in necrotic bone. MICROSURGERY 2004; 24(-1-):85-91. >>> Vascular endothelial growth factor 165; Phosphate buffer; albumin rabbit serum; Bone; Rabbit; 1003D; 3 days.

P6370 Manoonkitiwongsa,P.S., Schultz,R.L., McCreery,D.B., Whitter,E.F., Lyden,P.D. Neuroprotection of ischemic brain by vascular endothelial growth factor is critically dependent on proper dosage and may be compromised by angiogenesis. Journal of Cerebral Blood Flow and Metabolism 2004; 24(-6-):693-702. >>> Vascular endothelial growth factor; Saline; IA (carotid); Rat; 2001; 7 days; Controls received mp w/ vehicle; dose response (p. 697); stroke; ischemia (cerebral); biocompatible glue was used to secure catheter in artery.

P6459 Ward,W.K., Quinn,M.J., Wood,M.D., Tiekotter,K.L., Pidikiti,S., Gallagher,J.A. Vascularizing the tissue surrounding a model biosensor: how localized is the effect of a subcutaneous infusion of vascular endothelial growth factor (VEGF). BIOSENSORS&BIOELECTRONICS 2003; 19(-3-):155-163. >>> Vascular endothelial growth factor 165; PBS; BSA; SC; Rat; 2004; 28 days; Controls received mp w/ vehicle; no stress (see pg. 157); mp primed 40 hours at 38 degrees Celsius; "the rats tolerated the implants well without distress." (P.157); mp explanted at day 40.

P5966 Roguin,A., Avivi,A., Nitecki,S., Rubinstein,I., Levy,N.S., Abassi,Z.A., Resnick,M.B., Lache,O., Melamed-Frank,M., Joel,A., Hoffman,A., Nevo,E., Levy,A.P. Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES O F AMERICA 2003; 100(-8-):4644-4648. >>> DNA, naked; vascular endothelial growth factor, DNA; Water; IM; Mice; 2001; 7 days; Controls received mp w/ saline; tissue perfusion (quadriceps muscle); gene therapy; fenestrated catheter; pump implanted IP; "we have shown that when using plamid DNA, continuous administration is superior to multiple simultaneous IM injections." (p. 4647).

P5929 Namba,T., Koike,H., Murakami,K., Aoki,M., Makino,H., Hashiya,N., Ogihara,T., Kaneda,Y., Kohno,M., Morishita,R. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 2003; 108(-18-):2250-2257. >>> Immunoglobulin G; antibody, anti-vascular endothelial growth factor; IP; Rat; 28 days; Cardiovascular; peptides; pump model not stated; ischemia (hind-limb).

P5731 Sun,Y.J., Jin,K.L., Xie,L., Childs,J., Mao,X.O., Logvinova,A., Greenberg,D.A. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. Journal of Clinical Investigation 2003; 111(-12-):1843-1851. >>> Vascular endothelial growth factor; vascular endothelial growth factor R2/FC chimera; Phosphate buffer; BSA; Bone (tibia); Rabbit; 2ML2; 3 days; Controls received mp w/ vehicle; tissue perfusion (osteotomy site); replacement therapy (distraction osteogenesis); stability verified by in vitro assay for 2 weeks at 37 C. (p. 336);.

P5606 Harrigan,M.R., Ennis,S.R., Sullivan,S.E., Keep,R.F. Effects of intraventricular infusion of vascular endothelial growth factor on cerebral blood flow, edema, and infarct volume. Acta Neurochirurgica 2003; 145(-1-):49-53. >>> Vascular endothelial growth factor 165; PBS; BSA; CSF/CNS; Rat; 2001; 7 days; Controls received mp/ w vehicle; cardiovascular; peptides; ALZET brain infusion kit used; VEGF was recomb. human; ischemia (cerebral).

R0231 Freedman,S.B., Isner,J.M. Therapeutic angiogenesis for coronary artery disease. Ann.Intern.Med. 2002/1/1; 136(-1-):54-71. >>> Vascular endothelial growth factor; Periadventitial; Pig; 3,4 weeks; Replacement therapy (coronary ligation); cardiovascular; ischemia (cardiac); review, pg. 59.

P5978 Luttun,A., Tjwa,M., Moons,L., Wu,Y., Angelillo-Scherrer,A., Liao,F., Nagy,J.A., Hooper,A., Priller,J., De Klerck,B., Compernolle,V., Daci,E., Bohlen,P., Dewerchin,M., Herbert,J.M., Fava,R., Matthys,P., Carmeliet,G., Collen,D., Dvorak,H.F., Hicklin,D.J., Carmeliet,P. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1. Nature Medicine 2002; 8(-8-):831-840. >>> Placental growth factor; vascular endothelial growth factor; SC; Mice; 2001; 7 days; Angiogenesis.

P5323 Proescholdt,M.A., Jacobson,S., Tresser,N., Oldfield,E.H., Merrill,M.J. Vascular endothelial growth factor is expressed in multiple sclerosis plaques and can induce inflammatory lesions in experimental allergic encephalomyelitis rats. Journal of Neuropathology and Experimental Neurology 2002; 61(-10-):914-925. >>> Vascular endothelial growth factor; PBS; Albumin, rabbit serum; CSF/CNS (sciatic nerve); Rabbit; 1003D; 12 days; Controls received mp w/ vehicle; tissue perfusion (sciatic nerve graft); peptides; human recomb. VEGF used; transplantation;.

P5197 Masaki,I., Yonemitsu,Y., Yamashita,A., Sata,S., Tanii,M., Komori,K., Nakagawa,K., Hou,X., Nagai,Y., Hasegawa,M., Sugimachi,K., Sueishi,K. Angiogenic gene therapy for experimental critical limb ischemia: acceleration of limb loss by overexpression of vascular endothelial growth factor 165 but not of fibroblast growth factor-2. Circ.Res 2002/5/17; 90(-9-):966-973. >>> Antibody, anti-Vascular Endothelial Growth Factor; Immunoglobulin G; IP; Mice; 1007D; 7 days; Peptides; VEGF levels checked by ELISA; ischemia (limb).

P5132 Yang,R.H., Ogasawara,A.K., Zioncheck,T.F., Ren,Z., He,G.W., DeGuzman,G.G., Pelletier,N., Shen,B.Q., Bunting,S., Jin,H.K. Exaggerated hypotensive effect of vascular endothelial growth factor in spontaneously hypertensive rats. Hypertension 2002; 39(--):815-820. >>> Vascular Endothelial Growth Factor; Saline; IV (jugular); rat; 7 days; controls received mp w/ vehicle; cardiovascular; antihypertensive.

P5053 Harrigan,M.R., Ennis,S.R., Masada,T., Keep,R.F. Intraventricular infusion of vascular endothelial growth factor promotes cerebral angiogenesis with minimal brain edema. Neurosurgery 2002; 50(-3-):589-598. >>> Vascular Endothelial Growth Factor; PBS; Albumin, bovine serum; CSF/CNS; CSF/CNS (cortex); CSF/CNS (third ventricle); rat; 2001; 7 days; controls received mp w/ vehicle; dose response (p. 591); half-life = 6 min. (p. 594); peptides; brain tissue distribution; VEGF was human recombinant; benefits of continuous infusion p. 594.

P5032 Krum,J.M., Mani,N., Rosenstein,J.M. Angiogenic and astroglial responses to vascular endothelial growth factor administration in adult rat brain. Neuroscience 2002; 110(-4-):589-604. >>> Vascular Endothelial Growth Factor; PBS; CSF/CNS (striatum); rat; 2001; 1, 3 or 7 days; controls received mp w/ vehicle; comparison of gelfoam sponge administration vs. mp infusion; stress/adverse reaction (p. 592) necrotic tissue or cavity around cannula; peptides; brain tissue distribution, VEGF was recombinant human; some controls received cannulas with no pump attached.

top of page

References on the Administration of Growth Factors Using ALZET® Osmotic Pumps

1. Epidermal Growth Factor

2. Fibroblast Growth Factor

3. Hepatocyte Growth Factor

4. Insulin-like Growth Factor

5. Nerve Growth Factor

6. Placental Growth Factor

7. Transforming Growth Factor

8. Vascular Endothelial Growth Factor

Sterile Catheter Tubing for Infusion Studies

References on the Administration of Growth Factors
Using ALZET^® Osmotic Pumps